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Abbreviations 
 
AR – adrenergic receptors  
BDNF – brain derived neurotrophic factor 
BG – basal ganglia 
CB – cerebellum 
DA – dopamine 
DAergic – dopaminergic 
DAT – dopamine reuptake transporters 
DBH – dopamine β-hydroxylase  
DSP-4 – N-(2-chloroethyl)-N- ethyl-2-bromobenzylamine 
FP-CIT – [123I]N-ω- fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) tropane 
LC – locus coeruleus 
MAO – monoamine oxidase 
MC – motor cortex  
MPTP – 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
NA – noradrenaline 
NET – noradrenaline reuptake transporter 
NAergic – noradrenergic 
PD – Parkinson disease 
SN – substantia nigra 
SNc – substantia nigra pars compacta 
SPECT – single photon computed tomography (SPECT) imaging 
TH – tyrosine hydroxylase 
VIM – thalamus vetro-intermedio-lateralis  
VMAT – vesicular monoamine transporter 
VTA – ventral tegmental area 
6-OHDA – 6-hydroxydopamine 
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ABSTRACT 
 
Although Parkinson disease (PD) is characterized by the degeneration of nigrostriatal dopamine 
(DA) neurons, historic and more recent anatomopathological studies documented also an 
involvement of the serotonergic and cholinergic systems as well as a profound loss of neurons 
from the locus coeruleus (LC), the major noradrenergic (NAergic) nucleus in the brain. 
In the following studies, I will provide preliminary evidence of a new provocative hypothesis on 
the significance of LC in conditioning Parkinson tremor. In particular, I speculate that, early at a 
disease stage, patients with PD and tremor might have an (hyper-)active LC-NAergic system, 
which would play a key role in the appearance of tremor itself. Furthermore, given a putative 
compensatory and possibly neuroprotective mechanism of noradrenaline (NA), an intact or hyper-
active NAergic system would be responsible for, and support the clinical observation of, a slower 
disease progression in PD patients with tremor. When verified, this hypothesis will define, for the 
first time at a physio-pathological level, two different clinical phenotypes (i.e. tremor dominant 
and akinetic-rigid PD) and possibly suggest new interventional strategies (targeting the NAergic 
system) to modify disease progression.  
A number of drugs that can modulate the NAergic system already exist, ripe for testing. There is 
no cure for PD, and understanding the cause and progression of the neurodegenerative process is 
as challenging as it is necessary. 
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BACKGROUND 
 
Parkinson disease 
Parkinson disease is a chronic, progressive, neurodegenerative disorder characterized by 
pathologic intraneuronal α-synuclein-positive Lewy bodies and neuronal cell loss. This process has 
been described as involving the dopaminergic (DAergic) cells of the substantia nigra (SN) pars 
compacta, later becoming more widespread in the central nervous system (CNS) as disease 
progresses. Recently, there has been a growing awareness that the disease progression may involve 
more caudal portions of the CNS and a peripheral nervous system prior to the clinical onset of the 
disease (Braak et al., 2003).  
The prevalence of PD steadily increases with age, affecting about 1% to 2% of the population older 
than 65 years, and over 3% of those older than 85 years (de Lau et al., 2006). Most age-adjusted 
prevalence rates are reported to be between 100 and 200 cases per 100,000. Estimates of the 
incidence of PD are more variable. Age is the strongest risk factor for PD. Interestingly, a recent 
large prospective study found that incidence rates rise steeply through age 89; then lifetime 
plateaus after age 90 (Driver et al., 2009). The incidence of PD has been reported to be higher in 
man than women, but only among patients older than 60 years (Taylor et al., 2007).  
The primary physio-pathological substrate of PD involves dopamine depletion in the striatum 
(Kish et al., 1988). The loss of greater than 50–60% of the DAergic neurons, primarily in the lateral 
ventral tier of the substantia nigra pars compacta (SNc), results in a marked reduction in dopamine 
concentrations (70–80%) in the striatum (mainly in the putamen). This disrupts corticostriatal 
processing and explains clinical symptoms such as rigidity and bradykinesia, but not resting 
tremor (see later; Pirker et al., 2003; Isaias et al., 2007). Of relevance, it is worth resaying that motor 
signs do not become apparent until ≈80% of the DA terminals have been lost, which suggests the 
existence of an impressive compensatory mechanism in the earlier stage (pre-symptomatic) of 
disease (Morrish et al., 1998; Marek et al., 2001). 
At a clinical level, PD is a syndrome characterized by resting tremor, slowness of movements 
(bradykinesia), rigidity and postural instability. Usually, these features present asymmetrically. 
The contralateral side is eventually affected, but the asymmetry persists throughout the disease 
course. By using the term shaking palsy, James Parkinson in his An Essay on the Shaking Palsy (1817) 
drew attention to tremor as a characteristic feature of PD. Parkinson tremor is defined as a 
rhythmic, oscillatory, involuntary movement. It is the initial symptom in 50% to 70% of patients. 
The resting tremor of PD has typically low frequency (4 Hz to 6 Hz) and it is characterized by a 
pill-rolling (supination-pronation) movement. It commonly affects the distal upper extremities but 
may also involve the lower extremities and face, with the chin tremor being particularly specific for 
PD. Some patients with PD complain of an internal, not visible, tremor, called inner tremor. 
Parkinson tremor is remarkable for several features: (1) it is neither a consistent nor a 
homogeneous feature across patients or within an individual patient’s disease course; (2) it may 
diminish or disappear in the end-stage of PD; (3) it occurs predominantly at rest and is reduced or 
disappears by action; (4) it increases in amplitude or can be triggered by maneuvers such as 
walking or psychological states as anxiety or stress (specific tasks, like simple arithmetic 
calculation, may induce stress-related tremor) (Deuschl et al., 1998); (5) it is not present during 
sleep; (6) it may be the predominant or the only clinical sign for years before the appearance of 
akinesia (see also Brooks et al., 1992); (7) it is typically refractory to medications. Of relevance, a 
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significant proportion of patients with PD never develops tremor. There is evidence that Parkinson 
tremor is associated with a distinct cerebellothalamic circuit (Fukuda et al., 2004; Timmermann et 
al., 2003) involving the ventral intermediate nucleus of the thalamus (VIM), motor cortex (MC), 
and cerebellum (CB). Tremor-related responses have been observed both in the basal ganglia (BG), 
(i.e. pallidus [Hurtado et al., 1999] and subthalamic nucleus [Raz et al., 2000; Levy et al., 2000]) and 
in the cerebello-thalamic circuit (Lenz et al., 1994). Interference (e.g. by means of deep brain 
stimulation) with either circuit can effectively suppress resting tremor (Benabid et al., 1991; Krack 
et al., 1997; Lozano et al., 1995). This suggests that resting tremor results from a pathological 
interaction between the BG and the CB-VIM-CM circuit. In particular, it has been suggested that 
the BG have a modulatory role in tremor genesis, whereas the CB-VIM-CM circuit drives the 
tremor on a cycle- by-cycle basis (Fukuda et al., 2004; Timmermann et al., 2003). However, to date 
it remains unknown how BG dysfunction in PD can drive the distinct CB-VIM-CM circuit into 
generating resting tremor (Rodriguez-Oroz et al., 2009). Indeed, despite converging evidence of 
independent oscillating circuits within a widespread “tremor-generating network” (Mure et al., 
2011), there is no conclusive explanation for the onset of tremor in what it is fundamentally a 
hypokinetic movement disorder. Moreover, the simple interplay between BG and CB-VIM-CM 
circuit would not explain many of the peculiar features of tremor in patients with PD, in particular 
its intermittent appearance (see Hypothesis statement). Interestingly, the presence of tremor as the 
initial symptom often confers a favorable prognosis with slower progression of the disease, and 
some have suggested the term “benign tremulous parkinsonism” for a subset of patients with 
minimal progression, frequent family history of tremor, and poor response to DAergic drugs 
(Brooks et al., 1992; Ghaemi et al., 2002; Marshall et al., 2003, Josephs et al., 2006; O’Suilleabhain 
2006). Although rest tremor is a well-recognized cardinal feature of PD, many PD patients have a 
postural tremor that is more prominent and disabling than the classic rest tremor. In addition to 
the rest and postural tremors, a kinetic tremor, possibly related to enhanced physiologic tremor, 
may also impair normal reach-to-grasp movement (Wenzelburger et al., 2000).  
Bradykinesia may be initially manifested by slowness in activities of daily living or lack of 
movements (Cooper et al., 1994; Touge et al., 1995; Giovannoni et al., 1999; Jankovic et al., 1999). 
Patients with bradykinesia experience difficulty maintaining the velocity and amplitude of 
movement. In addition, to whole-body slowness and impairment of fine motor movement, other 
manifestations of bradykinesia include micrographia (hand writing getting smaller while writing), 
hypophonia (quite monotone speech), hypomimia (loss of facial expression and decreased blink 
rate), drooling due to failure to swallow saliva (Bagheri et al., 1999) and reduced armswing when 
walking (loss of automatic movement) (see also Isaias et al., 2012, in Appendix). The 
pathophysiology of bradykinesia is not well understood, but it is thought to result from failure of 
BG output to reinforce the cortical mechanisms that prepare and execute the commands to move 
(from Jankovic, 2003). In recordings from single cortical neurons in free-moving rats, a decrease in 
firing rate correlated with haloperidol-induced bradykinesia, demonstrating that reduced 
dopamine action impairs the ability to generate movement and cause bradykinesia (Parr-Brownlie 
and Hyland, 2005). The pre-movement EEG potential (Bereitschaftspotential) is reduced in patients 
with PD, probably reflecting inadequate BG activation of the supplementary motor area (Dick et 
al., 1989). On the basis of electromyographic (EMG) recordings in the antagonistic muscles of PD 
subjects during a brief ballistic elbow flexion, Hallett and Khoshbin (1980) concluded that the most 
characteristic feature of bradykinesia was the inability to energize the appropriate muscles to 
provide a sufficient rate of force required for the initiation and maintenance of a large, fast 
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(ballistic) movement. Secondary factors that may contribute to bradykinesia include muscle 
weakness and rigidity. 
Rigidity, tested by passively flexing, extending, and rotating the body part, is manifested by 
increased resistance throughout the range of movement. At physical examination, cogwheeling is 
often encountered, particularly if there is associated tremor or an underlying, not yet visible, 
tremor. Rigidity may occur proximally (e.g., neck, shoulders, and hips) and distally (e.g., wrists 
and ankles). Symptomatically, rigidity is experienced as stiffness and can present as 
musculoskeletal concerns, such as frozen shoulder. On examination, resistance is consistent 
throughout the range of movement in all directions and is not velocity dependent. 
Postural instability, and gait disturbance, are less prominent in early PD and are rarely presenting 
symptoms. Indeed, in a recent study aimed to investigate the role of DAergic striatal innervation 
on upper limb locomotor synergies, we found no difference for lower limbs spatio-temporal gait 
parameters (i.e. stride length, stride time and stance) between PD patients at an early disease stage 
and healthy controls when walking at preferred gait speed (Isaias et al., 2012 in Appendix). Later in 
the course of PD, however, gait problems (such as loss of postural reflexes, festination, freezing, 
and more severe postural changes) can be severe and become the major source of disability. 
Festination is the feeling of the feet wanting to rush forward, thus the patient experiencing 
hastening of gait. Freezing of gait is an inability to take effective steps. Patients will describe their 
feet feeling “stuck to the floor”. Freezing of gait typically occurs with gait initiation, turning, and 
passing through narrow spaces. Gait disturbance is disabling and dangerous problem for patients, 
commonly leading to falls and injuries. 
Several other symptoms (e.g. urinary incontinence, visual hallucinations, psychosis, delusions, 
dementia, depression, anxiety, impulse control disorders, sleep maintenance, etc.) may accompany 
the clinical spectrum of patients with PD late at disease stage. Such a clinical heterogeneity in PD 
patients suggests different clinical-pathologic entities as a possible result of a variable involvement 
of several neurotransmitter systems (from Fahn and Jankovich, 2007; see also Hypothesis statement). 
In our studies, we carefully selected patients with PD to represent a putative in vivo model of 
striatal DAergic innervation loss, thus allowing to selectively investigate this pathway and its 
implication in locomotion (Isaias et al., 2012 in Appendix) or motor learning (Isaias et al., 2011 in 
Appendix). To do so, beside a detailed neurological investigation, personally performed, several 
clinical inclusion criteria were applied to exclude in particular for psychiatric disorders and 
cognitive decline (see also articles in Appendix). The clinical examination remains the standard for 
the diagnosis of idiopathic PD. Still, the accuracy of diagnosis by general neurologists reaches 70% 
and by movement disorders specialists approaches 90% (Hughes et al., 2002). In support, brain-
imaging studies may be performed (see below).  
PD has historically been considered predominantly a sporadic disorder, even though about 10% to 
15% of PD patients have familial genetic defects (Lee et al., 2006). Several genes causing familial 
forms of PD have been discovered in the last decade, providing important insights into the 
pathogenesis of PD. In 1997, pathogenic point mutations in the α-synuclein gene were found in 
some PD lineages, and α-synuclein was subsequently identified as a major component in the Lewy 
bodies that are common in sporadic PD cases (Polymeropoulos et al., 1997; Spillantini et al., 1997). 
PARK1 and PARK4 (PARK is a nomenclature used for genetic types of PD originally identified by 
linkage analysis) are caused by mutation (PARK1) or duplication/triplication (PARK4) of the α-
synuclein gene (SNCA) and are estimated to account for approximately 2% of autosomal dominant 
PD (Lesage and Brice, 2009). While the normal function of α-synuclein is not well understood, α-
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synuclein does have the ability to form insoluble aggregates that may disrupt DAergic 
transmission, synaptic vesicles, intracellular trafficking, and protein degradation (Lee et al., 2006). 
Many groups have attempted to investigate the function of normal and mutant α-synuclein by 
studying genetic mouse models. Recent studies involving both α-synuclein knockout mice and 
mice expressing the human pathogenic A30P α-synuclein mutation have shown that α-synuclein 
alters storage and metabolism of NA in addition to DA (Yavich et al., 2006). This suggests that the 
neuroprotective effect of NA may be reduced in PD patients with α-synuclein mutations (see later), 
making them less resilient in the event of DAergic neuron degeneration. Indeed, patients with 
SNCA mutations tend to have an earlier age at onset with frequent cognitive decline; additional 
cortical features not commonly seen in PD, such as aphasia, have been reported. Moreover, these 
patients have a less-robust response to DAergic therapy, further suggesting at a clinical level an 
additional, and possibly more prominent, involvement of NAergic system than the DAergic one. 
Other familial forms of PD include mutations in genes related to protein degradation. PARK2 is the 
most common type of autosomal recessive PD and is caused by mutation in the parkin gene, 
encoding for E3 ubiquitin-protein ligase, which normally functions to properly target proteins for 
proteosomal degradation. PARK2 is a prototypic cause of early-onset PD and may account for up 
to 50% of familial early-onset PD and about 20% of apparent sporadic early-onset PD (Lücking et 
al., 2000). These patients tend to have a high incidence of dystonic signs, especially affecting the 
lower extremities. They have a robust response to levodopa, even though a relatively short delay 
occurs before they develop motor fluctuations. A role for NA in parkin-related PD is supported by 
preliminary evidence that parkin knockout mice experience a distinct loss of LC neurons (von 
Coelln et al., 2004). Several other genes involved in the onset of PD have been identified but their 
relevance to the NAergic system has not been investigated yet.  
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In vivo imaging of dopaminergic striatal innervation 
Several radiotracers for Positron emission tomography (PET) and Single photon emission 
computed tomography (SPECT) have been successfully developed to assess the integrity of 
presynaptic DAergic neurons end postsynaptic receptors in humans (figure below). Above all, 
SPECT with FP-CIT ([123I]N-ω- fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) tropane) was 
shown to be very sensitive to detect loss of striatal DATs (particularly in the putamen) in early PD 
(for review Isaias and Antonini, 2010), and recent studies even suggest that DAT imaging may be 
able to detect nigrostriatal DAergic degeneration also in preclinical cases (Ponsen et al., 2004). 
Registration studies for FP-CIT were started in 1996. In 1998 and 1999, the results of phase-I and -II 
studies were published, respectively (from Booij et al., 1998; Booij et al., 1999), followed by 
multicenter phase-III and -IV studies in 2000 and 2004 (Benamer et al., 2000; Catafau et al., 2004). In 
2000, FP-CIT was licensed as DaTSCANTM in Europe to differentiate patients with a parkinsonian 
syndrome (i.e. PD, multiple system atrophy, or progressive supranuclear palsy) from essential 
tremor (ET). In clinical practice, DAT imaging by means of SPECT and FP-CIT has the capability to 
discriminate PD patients with DAergic cell loss from those with other forms of Parkinsonism not 
characterized by loss of presynaptic DAergic cells (e.g., psychogenic parkinsonism and drug-
induced postsynaptic parkinsonism) (Isaias and Antonini, 2010). On the contrary, SPECT and FP-
CIT is not a valid tool to discriminate among neurodegenerative parkinsonism (Isaias et al., 2012 in 
Appendix). In our studies, besides supporting the clinical diagnosis, DAT imaging provided a 
measurement of DAergic striatal loss thus allowing correlations with behavioral and 
biomechanical measurements (see Isaias et al., 2011 and 2012, in Appendix). In these studies, SPECT 
imaging was performed in collaboration with Dr. Giorgio Marotta and the Department of Nuclear 
Medicine of the Ospedale Maggiore Policlinico (Milano). For imaging acquisition and 
reconstruction we have always applied similar methods. Briefly, intravenous administration of 
110–140 MBq of FP-CIT was performed 30–40 minutes after thyroid blockade (10–15 mg of Lugol 
oral solution) in all patients. Brain SPECT was performed 3 hours later by means of a dedicated 
triple detector gamma-camera (Prism 3000, Philips, Eindhoven, the Netherlands) equipped with 
low-energy ultra-high resolution fan beam collimators (4 subsets of acquisitions, matrix size 128 × 
128, radius of rotation 12.9–13.9 cm, continuous rotation, angular sampling: 3 degree, duration: 28 
minutes). Brain sections were reconstructed with an iterative algorithm (OSEM, 4 iterations and 15 
subsets), followed by 3D filtering of sections obtained (Butterworth, order 5, cut-off 0.31 pixel-1) 
and attenuation correction (Chang method, factor 0.12). Data analysis differed according to the aim 
of the study (see Appendix). 
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Figure as in Isaias et al., Future Neurology 2012 (in appendix). FP-CIT SPECT images and 
binding values of one healthy subjects (HC, left in the picture) and two patients with PD. Please 
note the great asymmetry of the two hemispheres with regards to binding values and the greater 
involvement of the putamen than the caudate nucleus in both patients. 
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The locus coeruleus and its relevance to Parkinson disease 
The first description of the LC by Reil dates from 1809 (Reil, 1809). Wenzel and Wenzel (1812) first 
used the term “locus coeruleus”. In 1909, Jacobsohn described the presence in the cell bodies of the 
LC of melanin granules (Jacobsohn, 1909). In 1959, the highest activity of monoamine oxidase 
(MAO) in the brain was demonstrated in neurons of the rodent LC using enzyme histochemistry 
(Shimizu et al., 1959). In 1970s, NAergic projections from the LC were identified (Fuxe et al., 1970; 
Ungerstedt  et al., 1971). 
The neurons of the LC form a distinct, compact cell group largely contained within the central gray 
of the isthmus, medial to the mesencephalic nucleus of the trigeminal nerve (Russel, 1955). Due to 
the very small size of the LC, biochemical studies are unable to differentiate LC nucleus vs. 
surrounding areas. In humans, the LC has a rostrocaudal extension of approximately 16 mm 
(Broadal, 1981; German et al., 1988); it begins slightly rostral to the main trigeminal nucleus and 
extends rostrally as far as the level of the mesencephalic trigeminal nucleus. The nucleus is a tube-
like shape, and it consists of two kinds of neurons. The major cell type in the LC is the medium-
sized neuron which possess a multipolar arborization and contains neuromelanin (NM) granules; 
intermingled with these neurons; a second group of cells consist of smaller non-catecholamine 
neurons with various shape and dendritic arborization (Olszewski et al., 1954; Patt et al., 1993). The 
cell density is highest in the caudal portion of the nucleus and decreases rostrally. The LC cells 
have been quantified by different researchers in different animal species both by measuring the 
NM content and by using immunocytochemistry for the enzyme tyrosine hydroxylase (TH). These 
studies measured about 19,000 NA neurons in the LC nucleus sensu stricto (Vijayashankar et al., 
1979) and 60,000 NA neurons in the LC (LC sensu stricto with pericoerulear NA nuclei) of young 
adults, which decrease to 40,000 in normal elderly subjects (Iversen et al., 1983; Baker et al., 1989). 
Many retrograde and anterograde tract tracing studies over the years, that have been well 
recapitulated by Aston-Jones (2004), Samuels and Szabadi (2008a,b) and Benarroch (2009), have 
demonstrated the numerous afferent and efferent connections of LC neurons.  
The LC is the major source of NA in the brain, with projections throughout most central nervous 
system (CNS) regions, including the cerebral cortex, hippocampus, thalamus, midbrain, brainstem, 
cerebellum, and spinal cord (reviewed by Aston-Jones et al., 1995 and Samuels and Szabadi 
2008a,b). Using a histofluorescence method, Falck and coll. (Falk et al., 1962) identified two main 
ascending pathways from the LC. A dorsal one (Levitt et al., 1949), innervates the entire cerebral 
cortex, especially motor and premotor areas, the olfactory tubercle, the septum, the bed nucleus of 
the stria terminalis, the hippocampal formation and the amygdala (Fuxe et al., 1970; Maeda et al. 
1972). A ventral or intermediate pathway supplies the hypothalamus, overlapping with NA 
projections coming from the A1 and A2 regions. In addition, fibers have been described from the 
LC to the subthalamic nucleus (Rinvik et al., 1979), the SN (Collingridge et al. 1979), and the ventral 
tegmental area (VTA) (Jones et al., 1977) and others pass via the superior cerebellar peduncle to the 
cerebellum (Olson et al., 1971), while a caudal projection has been traced to the reticular formation 
(Olson et al., 1972). 
Synaptic inputs from several sources influence the activity of LC neurons (reviewed by Aston-
Jones et al., 1995). This nucleus is densely innervated by fibers that contain opiates, glutamate, 
gamma-aminobutyric acid (GABA), serotonin, epinephrine, and orexin/hypocretin. The sources of 
these various inputs have not been fully elucidated, though some major inputs have been 
identified. The nucleus paragigantocellularis in the ventrolateral rostral medulla, a major input that 
strongly excites LC neurons, is a source for glutamate, GABA, enkephalin, corticotropin-releasing 
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hormone (CRH), and adrenaline. The orbitofrontal and anterior cingulate cortices also provides a 
strong glutamatergic afferent drive to the LC. Inhibitory GABA and enkephalin input originates 
from the dorsomedial rostral medulla. Orexin/hypocretin inputs originate in the hypothalamus, 
(Horvath et al., 1999) as do histaminergic inputs (Pollard et al., 1978). The extensive shell of 
dendrites that surrounds the LC nucleus offers additional extensive targets for afferent 
termination, and indeed it appears that several areas target these extranuclear dendrites that do not 
innervate the LC nucleus proper. Thus, projections from the periaqueductal gray matter, (Ennis et 
al., 1991; Bajic et al., 2000) parabrachial region, (Luppi et al., 1995) preoptic area, (Rizvi et al., 1994; 
Steininger et al., 2001) amygdala, (Van Bockstaele et al., 1998), medial prefrontal cortex, 
suprachiasmatic nucleus using the dorsomedial hypothalamus as a relay, among other sites, 
project to the peri-LC region.  
LC neurons fire in two distinct modes, tonic and phasic (Aston-Jones and Cohen, 2005a,b). Tonic 
activity is characterized by a sustained and highly regular pattern of discharge that is highest 
during wakefulness and decreases during slow-wave sleep. This tonic activity plays a central role 
in the sleep-waking cycle anticipating the fluctuations of electroencephalographic activity and 
promoting a state of vigilance. It is indeed well known that the stimulation of central NAergic 
receptors leads to changes in the state of vigilance. There is also a sustained increase in tonic 
discharge rate in response to environmental stimuli that elicit behavioral arousal and exploratory 
behavior. During focused attention and accurate task performance, LC neurons reduce their tonic 
firing to a moderate rate and respond phasically to task-relevant stimuli. The phasic bursts of LC 
activity are closely associated with highly accurate behavioral responses (Berridge and 
Waterhouse, 2003; Aston-Jones and Cohen, 2005a). 
Two subtypes of adrenergic receptors (ARs) have been described: alpha ARs (α1and α2) and beta 
ARs (β1, β2, and β3). These ARs are found throughout the brain including the striatum and SN. 
Different subtypes are coupled to different G proteins. In general, excitatory effects are mediated 
by α1 and β postsynaptic ARs (McCormick and Wang, 1991; McCormick et al., 1991; Arcos et al., 
2003) and inhibitory effects by α2 presynaptic ARs (Belujon et al., 2007; Benarroch, 2009). Once 
released into the extracellular space, reuptake of NA is performed by the noradrenaline reuptake 
transporter (NET) (Rascol et al., 2001), while extracellular NA also limits its own release through 
the stimulation of auto-inhibitory α2 ARs (reviewed by Delaville et al., 2011). 
To elucidate the way NA could modulate the DAergic system function and play a role in the 
progression and expression of PD, it is critical to summarize the intimate molecular, functional, 
and anatomical relationships between NA and DA. First, NA and DA share a biosynthetic pathway 
and DA is in fact the direct precursor of NA (Molinof et al., 1971). In NAergic neurons dopamine β-
hydroxylase (DBH) acts within the synaptic vesicles to convert DA to NA. Second, NAergic 
neurons directly innervate midbrain DA neurons and the striatum. Stimulation of the LC facilitates 
burst firing of SNc neurons, while administration of the α1 ARs antagonist prazosin attenuates 
firing (Grenhoff et al., 1993), and either lesion of the LC or chronic NA depletion decrease striatal 
DA release (Lategan et al., 1990; Lategan et al., 1992). Furthermore, the peri-LC region receives also 
DAergic inhibitory control from the VTA (Javoy-Agid et al., 1980; Guiard et al., 2008). Although 
some of these projections have been shown to contact LC dendrites, additional ultrastructural 
studies are needed. Finally, DBH, NA, and NET can be detected in the midbrain and striatum 
(Udenfried et al. 1959, Glowinski et al. 1966, Ross et al. 1974, Liprando et al., 2004) and, as in other 
regions of the brain, striatal NA release is controlled by both NET and α2 ARs (Gobert et al., 2004, 
Yavich et al., 1997 and 2003).  
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Only a few studies investigated the role of DA in the modulation of NAergic pathways in subjects 
with PD. In general, a decrease in DAergic neuron function seems to enhance NAergic system 
activity. Rats with a selective DAergic neuron lesion by 6-hydroxydopamine (6-OHDA) show an 
increase in firing rate of LC neurons (Wang et al., 2009) as well as an upregulation of β ARs in the 
cerebral cortex, the forebrain, thalamic nuclei, the midbrain, the hippocampus, and the CB 
(Johnson et al., 1989). Ponzio et al. (1981) demonstrated that NAergic nerve terminals originating 
from the LC might be involved in regulating the functional activity of the DAergic nerve terminals 
both in the cerebral cortex and the striatum. This regulation appears to be excitatory in nature and 
is present early in development. These data are confirmed by pharmacological studies showing 
that αl ARs antagonism may reduce the sensitivity of the mesolimbic DAergic system to 
pharmacological or environmental challenge (Davis et al., 1985; Snoddy and Tessel, 1985; Auclair et 
al., 2002).  
The first hints that NA promotes DA neuron survival came from 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) studies in nonhuman primates and mice. Both Mavridis and coll. 
(Mavridis et al., 1991) and Fornai and coll. (Fornai et al., 1994) described that the MPTP-induced 
damage to nigrostriatal DA neurons was enhanced by pre-treatment with N-(2-chloroethyl)-N- 
ethyl-2-bromobenzylamine (DSP-4), a selective LC neurotoxin (see also On-going research activities). 
Furthermore, the tottering mouse, which has NAergic hyper-innervation and increased levels of 
NA throughout the forebrain, was protected from MPTP toxicity (Kilbourn et al., 1998; Hein et al., 
1999). Rommelfanger and coll. also showed that either pharmacological or genetic blockade of NET 
protects DA neurons from MPTP damage in mice (from Rommelfanger et al., 2004). Despite 
preliminary evidence of a neuroprotective activity of NAergic system over DA neurons, it has not 
been well elucidated, at a molecular level, how this can happen. A possible explanation might 
relate to the release by LC neurons of co-transmitters galanin and brain derived neurotrophic 
factor (BDNF), two potential molecules for neuroprotection (Rommelfanger and Weinshenker, 
2007). Indeed, the central NA system, apart from target neurons, includes effects on glia and brain 
vessels (Harik et al., 1984; Stone et al., 1989). This is in line with the morphology of NA axons that 
possess varicosities (bouttons en passage) rather than classic (bouttons terminaux) typical of non-
monoaminergic axon terminals. Finer morphological studies of NA axons arising from the LC have 
shown that axon terminals are thin, with small (0.5 µm) beaded varicosities. This contrasts with NA 
axons arising from the medullary A1 and A2 cell groups which branch out with terminals featuring 
large (1±3 µm) beaded varicosities. It is worth mentioning that monoaminergic axons with smaller 
beaded varicosities possess a lower threshold to various neurotoxic insults and at the same time 
are more affected in degenerative diseases. These combined findings call for more in depth studies 
aimed at relating the cell biology of synaptic varicosities with the selective cell death occurring 
both in neurotoxic insults and in neurodegenerative disorders (from Gesi et al., 2000). 
Apart from its importance for the survival of DA neurons, NA could also play an independent role 
in the symptoms of PD. Mavridis et al. (1991) have suggested that the activation of α1 ARs, which 
results in an increase in NAergic tone, facilitates locomotor activity, whereas α2 ARs activation, by 
decreasing NAergic tone, inhibits locomotor activity. In the reserpine rat (see also On-going research 
activities), yohimbine, a α2 ARs antagonist, blocked tremor and improved rigidity but not 
hypokinesia (Colpaert, 1987). In the 6-OHDA rat and MPTP monkey models of PD, blockade of α2 
ARs by idazoxan improved motor disabilities (Bezard et al., 1999; Belujon et al., 2007) in a manner 
comparable to that induced by a minimal dose of levodopa (Bezard et al., 1999). Still, idazoxan as a 
monotherapy in PD patients did not show any anti-parkinsonian effect (Henry et al., 1999; Rascol 
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et al., 2001; Colosimo and Craus, 2003). Interestingly, the α2 AR agonist clonidine and β ARs 
blockers (e.g. propranolol) are effective in treating akathisia and tardive dyskinesia (Wilbur et al., 
1988). More recently, von Coelln and coll. described that in parkin null mice (by targeted deletion of 
parkin exon 7) there is a dramatic reduction of NAergic neurons, while the nigrostriatal DAergic 
system does not show any impairment. Thus suggesting an earlier involvement of NAergic 
neurons in parkin positive PD patients (von Coelln et al., 2004). In addition to the spectrum of 
movement abnormalities, many PD patients experience neuropsychiatric symptoms (such as 
cognitive impairment and depression) that may be also related to LC degeneration (Chaudhuri et 
al., 2006). Non-motor symptoms also improve by the use of selective α1 AR agonists. For example, 
naphtoxazine reduced the errors and restored the lateralization of N100 during the shifting 
reaction time task, suggesting that it may act on the processes underlying the shifting deficit in PD 
patients (Bedard et al., 1998). PD patients with comorbid depression tend to exhibit more 
pronounced PD symptoms, and their depression can be alleviated by reboxetine, a specific NA 
reuptake inhibitor (Lemke, 2002; Papapetropoulos et al., 2006; Pintor et al., 2006). Recently, 
however, another NET inhibitor atomoxetine failed to reduce depression in PD patients 
(Weintraub et al., 2010). The use of selective NET inhibitors may be critically dependent on the 
status of NA neurons.  
Finally, the death of NA neurons may modulate the plastic changes and behavioral pathology 
associated with long-term levodopa therapy (see also Summary and future directions). Although DA 
replacement with levodopa remains one of the most effective treatments for PD, adverse events 
such as dyskinesia may appear (Rascol et al., 2001). Human and animal studies have shown that α2 
ARs antagonists provide relief from levodopa-related dyskinesia (Grondin et al., 2000; Archer et 
al., 2003). Of relevance, while the mechanism of dyskinesia and the basis of the relief provided by 
blockade of α2 ARs remains unknown, these data imply that NA continues to function in 
modulating the plasticity and activity of the basal ganglia during the progression of PD (see also 
Hypothesis statement).  
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HYPOTHESIS STATEMENT AND AIMS 
 
In my routine movement disorders clinical practice I have often wondered on the great 
heterogeneity of clinical presentation of patients with PD. In time, I start believing that such a 
variety of phenotypes may represent different physio-pathological pattern of neuronal 
degeneration. To some extent, we might call PD different diseases sharing DAergic striatal 
innervation loss as a solely common feature. My interest was mainly captured by patients with 
prominent resting tremor that persistently overshadowed other signs of PD throughout the disease 
course. Remarkably, they also referred no more than mild progression, despite over seven years 
from motor symptoms onset.  
I speculate that the LC is involved in the generation of Parkinson tremor. LC-NAergic activity 
would play a key role in tremor onset by directly influencing the CB-VIM-CM circuit. Accordingly, 
some PD patients would have a hyperactive LC-NAergic system, especially early at a disease (pre-
motor) stage. Moreover, given a putative compensatory and neuroprotective activity (Srinivasan 
and Schmidt, 2003; von Coelln et al., 2004), an intact NAergic system would be related to the more 
benign disease progression of these patients. In addition to Parkinson tremor, an intact and 
possibly hyperfunctioning LC might possibly contribute to other NA-related signs, such as anxiety 
and REM sleep behavior disorder. On the contrary, subjects with a DAergic and NAergic parallel 
degeneration would show depression, hyposmia and a more aggressive disease progression. 
Preliminary evidence of a role of adrenaline and NA in Parkinson tremor emerged from studies 
published in the 1960s and 1980s (Constas, 1962; Colpaert, 1987; Wilbur et al., 1988). In time, 
several independent investigators described that experimental lesions of the LC exacerbate PD 
pathology and symptomology (e.g. depression, dementia, etc.) (see Background). All these studies, 
however, were carried out under the assumption that PD presents a wider spectrum of motor and 
non-motor signs related to combined aminergic deficiencies. Although it is relatively common to 
describe a variety of significant biochemical alterations in PD patients, it is more difficult to 
demonstrate, for each neurotransmitter, a specific role in the pathophysiology of the disease. This 
point has been addressed solely by post-mortem studies that correlated a specific biochemical 
pattern observed in a given patient with his clinical history (McMillan et al., 2011). This approach 
bares several limitations. In particular, it describes the end-stage of the disease and cannot provide 
any useful information on the pathophysiological changes along with disease progression. In 
particular, compensatory mechanisms along the disease course will not be revealed by these 
studies. 
In time we achieved comprehensive information on LC, at least at an anatomical and physiological 
level (for review: Samuels and Szabadi, 2008a,b). It is therefore possible, within a reasonable 
timeframe, to apply such knowledge to investigate LC-NAergic activity in PD patients. In addition, 
new NA-specific tracers for PET will be available soon for human studies thus allowing a direct in 
vivo investigation of LC activity. Two possible outcomes make the research line proposed of 
significant value. First, many drugs targeting the NAergic system (e.g. NA reuptake inhibitor; L-
Threo-Dops; α2 receptors antagonist, etc.) (for review Delaville et al., 2011) are already available 
and could be used to possibly ameliorate quality of life of PD patients. A better understanding of 
LC-NAergic activity in PD sub-groups of patients is therefore mandatory. Second, if a 
compensatory and neuroprotective role of NAergic system over DA cell loss will be proven, we 
envision new therapeutic options to slow disease progression. 
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Introduction to Research activities and Methods  
In the following sections I will present and discuss published and on-going research activities 
investigating the LC-NAergic activity in patients with Parkinson tremor.  
Studying the LC can be challenging to say the least. In particular, (1) directly recording in humans 
the activity of LC is not applicable given its anatomical structure and location; (2) the size of LC is 
at the spatial resolution limits of currently available imaging techniques; and (3) even receptor 
binding (or displacement) studies and PET might not catch its phasic electrical activity; (4) last, 
there are no PET tracer available at the moment to target specifically the NAergic system and the 
LC in particular (Logan et al., 2007). Despite being an evident clinical sign, Parkinson tremor is also 
difficult to describe especially given its unpredictable and intermittent appearance (see 
Background). A great effort was therefore required to investigate a putative correlation between LC-
NAergic and Parkinson tremor. To do so, we applied a multidisciplinary approach including brain-
imaging techniques (e.g. SPECT and MRI), EMG recordings of tremor during behavioral tasks, as 
well as studies in animal models of PD.  
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COMPLETED RESEARCH ACTIVITIES 
 
 
Alles sollte so einfach wie möglich gemacht werden, aber 
nicht einfacher.    
[A. Einstein] 
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Enhanced catecholamine transporter binding in the locus 
coeruleus of patients with early Parkinson disease 
Isaias IU, Marotta G, Pezzoli G, Sabri O, Schwarz J, Crenna P, Classen J, Cavallari P.  
BMC Neurol. 2011;11:88. 
 
This first study aimed to demonstrate a putative functional integrity of LC-NA system in PD 
patients early at a disease stage.  
We retrospectively reviewed clinical and imaging data of 94 PD patients and 15 healthy subjects 
who underwent SPECT imaging with FP-CIT. Although FP-CIT is mainly used to measure striatal 
DAT (see Background)., it has shown sensitivity, albeit lower, to NET (Booij et al., 2008), thus 
allowing to possibly investigating also the LC. To do so, besides a voxel-based whole brain 
analysis, we also applied a volume of interest (VOI) analysis of a priori defined brain regions, 
focusing on the LC. PD patients were selected only if at early clinical stage (Hoehn and Yahr stage 
1 or 2) and according to several other inclusion criteria (see article Methods-Subjects).  
Average FP-CIT binding in the putamen and caudate nucleus was significantly reduced in PD 
patients (43% and 57% on average, respectively; p < 0.001 Student’s t-test), thus confirming the 
clinical diagnosis of PD. In contrast, subjects with PD showed an increased FP-CIT binding in the 
LC (166% on average; p < 0.001 Student’s t-test) (see article Figure 1 [also below]). More 
interestingly, LC-binding correlated negatively with striatal FP-CIT binding values (caudate: 
contralateral, r = -0.28, p < 0.01 and ipsilateral r = -0.26, p < 0.01; putamen: contralateral, r = -0.29, p 
< 0.01 and ipsilateral r = -0.29, p < 0.01) (see article Figure 2).  
These preliminary data are consistent with higher baseline catecholamine transporter binding in 
the LC region of patients with PD at an early stage, which is well compatible with enhanced NA 
release (Metzger et al., 2002; Zahniser et al., 2009).  
The relevance of this study relies on the fact that we were able to show, for the first in vivo, an 
integrity and possibly hyperactivity of LC-NAergic system in subjects with PD. These findings 
must be carefully interpreted due to several limitations. In particular, our results derived from the 
analysis of the binding of FP-CIT, a 123I-labeled cocaine derivative with high affinity for DAT (KD = 
2nM) and a lesser affinity towards NET (KD = 140 nM) (Booij et al., 2008). Still, we believe it is 
unlikely that the higher binding observed in the LC area is due to an enhanced DAergic, rather 
than NAergic, transporter counts. Indeed, DAT are poorly represented in the LC area (Javoy-Agid 
et al., 1980). On the contrary, a major NET component is synthesized in the cell body of LC 
pigmented neurons and exposed on their membrane to be transferred toward axonal terminals 
(Zahniser and Sorkin, 2009), with a less consistent NET component localized on terminal 
projections arising from more caudal NAergic cell groups (Ordway et al., 1997). Ideally, the LC-NA 
system and NET should be investigated in vivo by dedicated, highly specific radiotracers 
displaying low background non-NET binding, high sensitivity to variations in NET density and 
fast kinetics (Logan et al., 2007). We hope that such radiotracers will be available soon for more 
accurate studies.  
Our results might be at odd with neuropathological findings where frank neuronal degeneration 
has been recognized within LC. Indeed, morphologic hallmarks of sporadic PD (i.e. Lewy bodies 
and dystrophic neurites containing pathologic a-synuclein) may appear initially in the lower 
brainstem (Braak et al., 2003). Still, this information was derived from anatomopathological studies 
of patients at the end-stage of the disease and therefore is poorly comparable with our findings, 
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based on subjects with mild clinical signs (see article Methods-Subjects). In addition, such previous 
studies report data only on a limited number of patients poorly described at a clinical level (e.g. the 
presence of depression or cognitive impairment) (Hoogendijk et al., 1995; McMillan et al., 2011). 
Last, Lewy pathology can correlate poorly with neuronal loss in specific areas, thus its validity in 
predicting neuronal disintegration is questionable (Jellinger, 2009). Indeed, NAergic neurons in the 
LC are relatively preserved in early PD and do not exhibit the same intracellular changes as in the 
SN (Halliday et al., 2005). Accordingly, neuromelanin-sensitive imaging methods in vivo (Sasaki et 
al., 2006) suggests [see also On-going research activities] that the loss of NA neurons in PD may be 
confined to the larger, pigmented cells localized in the caudal part of the nucleus, whereas small 
unpigmented cells are increased in number, as if derived from shrinkage of larger neurons 
(Hoogendijk et al., 1995). 
Last, it is worth mentioning that we are currently not able to identify non-symptomatic subjects 
with (at high risk for) PD. Therefore, it was not possible to investigate subjects at a pre-clinical (pre-
motor) PD stage. Still, we could have investigated subjects with a genetic mutation (e.g. LRRK2) 
but yet no clinical signs evocative for PD. Several difficulties prevented such a study. First of all, 
the ethical issue in offering a study aimed to define, at this stage, only the risk to develop the 
disease itself. Second, physio-pathological PD-related pathways are not yet clear in genetically 
defined Parkinsonism and may not necessarily correspond to idiopathic PD.  
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Figure 1 in Isaias et al., BMC Neurol. 2011;11:88 here with detailed statistical analysis [SPM] (see 
article for description). 
 
  
RESEARCH ARTICLE Open Access
Enhanced catecholamine transporter binding in
the locus coeruleus of patients with early
Parkinson disease
Ioannis U Isaias1,2,3*, Giorgio Marotta4, Gianni Pezzoli2, Osama Sabri5, Johannes Schwarz3, Paolo Crenna1,
Joseph Classen3 and Paolo Cavallari1
Abstract
Background: Studies in animals suggest that the noradrenergic system arising from the locus coeruleus (LC) and
dopaminergic pathways mutually influence each other. Little is known however, about the functional state of the
LC in patients with Parkinson disease (PD).
Methods: We retrospectively reviewed clinical and imaging data of 94 subjects with PD at an early clinical stage
(Hoehn and Yahr stage 1-2) who underwent single photon computed tomography imaging with FP-CIT ([123I] N-ω-
fluoropropyl-2b-carbomethoxy-3b-(4-iodophenyl) tropane). FP-CIT binding values from the patients were compared
with 15 healthy subjects: using both a voxel-based whole brain analysis and a volume of interest analysis of a priori
defined brain regions.
Results: Average FP-CIT binding in the putamen and caudate nucleus was significantly reduced in PD subjects
(43% and 57% on average, respectively; p < 0.001). In contrast, subjects with PD showed an increased binding in
the LC (166% on average; p < 0.001) in both analyses. LC-binding correlated negatively with striatal FP-CIT binding
values (caudate: contralateral, r = -0.28, p < 0.01 and ipsilateral r = -0.26, p < 0.01; putamen: contralateral, r =
-0.29, p < 0.01 and ipsilateral r = -0.29, p < 0.01).
Conclusions: These findings are consistent with an up-regulation of noradrenaline reuptake in the LC area of
patients with early stage PD, compatible with enhanced noradrenaline release, and a compensating activity for
degeneration of dopaminergic nigrostriatal projections.
Background
The pontine nucleus locus coeruleus (LC) is the major
site of noradrenaline (NA) neurons in the central ner-
vous system, hosting almost half of the NA-producing
neurons in the brain [1].
The LC may play an important role in the pathophy-
siology of Parkinson disease (PD) for several reasons: (i)
as a site of neuronal degeneration as part of PD pathol-
ogy; [2] (ii) as the anatomical origin of projections mod-
ulating dopaminergic action of the substantia nigra; [3]
(iii) as a structure under putative dopaminergic inhibi-
tory control from the ventral tegmental area (VTA)
which is known to degenerate in PD [4,5]. Based on
physiological functions ascribed to the noradrenergic
system, impaired functioning of LC in PD has been
associated primarily to affective disorders, [6] cognitive
disturbances, [7] sleep disorders, [8] sensory impairment
[2] and autonomic dysfunction [9]. Through its interac-
tions with the dopaminergic system however, the LC
may also have a less direct role in the pathogenesis of
PD via (i) an interplay of catecholamine systems with
one amine cross-talking with receptors belonging to the
other system [10,11] or (ii) extra-synaptic neuro-modu-
latory, metabotroic and trophic activities of noradrena-
line itself [12].
Information on the LC in PD is mainly based on post-
mortem examination of histopathological specimens,
while information on its in vivo function is largely
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absent. Ideally, the LC-NA system and noradrenaline
molecular transporters (NET) should be investigated in
vivo by dedicated, highly specific radiotracers displaying
low background non-NET binding, high sensitivity to
variations in NET density and fast kinetics. As such a
radiotracer is not available for large clinical studies, [13]
we employed single photon computed tomography
(SPECT) with FP-CIT ([123I] N-ω-fluoropropyl-2b-car-
bomethoxy-3b-(4-iodophenyl) tropane) in a large, homo-
geneous cohort of early stage PD patients. Although FP-
CIT is mainly used for assessing striatal dopamine reup-
take transporters, it has shown sensitivity, albeit lower,
to NET [14]. Therefore, when applied to an anatomical
region with known low dopamine reuptake transporter
capacity such as the LC, it allows investigation of the
NA-dependent synaptic activity.
Methods
Subjects
We retrospectively reviewed clinical and imaging data of
94 subjects with idiopathic PD in whom FP-CIT SPECT
was performed at the “Ospedale Maggiore Policlinico”
in Milano within five years of the onset of motor symp-
toms. Fifteen healthy subjects (healthy controls, HC)
were prospectively enrolled for comparisons of FP-CIT
binding. At the time of SPECT, HC did not suffer from
any disease and were not taking any medications. Clini-
cal inclusion criteria for subjects with PD were: (a) diag-
nosis according to the UK Parkinson Disease Brain
Bank criteria; (b) absence of any signs indicative for aty-
pical parkinsonism (e.g. gaze abnormalities, autonomic
dysfunction, significant psychiatric disturbances, etc.)
over a follow-up period of at least three years after
symptoms onset; (c) Hoehn and Yahr (H&Y) stage 1 or
2 in drugs-off state (i.e. after overnight withdrawal of
specific drugs for PD; no patients were taking long-act-
ing dopaminergic drugs) at the time of SPECT; (d) posi-
tive clinical improvement at Unified Parkinson Disease
Rating Scale (UPDRS) after L-Dopa intake (i.e. > 30%
from drug-off state) at some point during the three
years of follow up; (e) a normal Magnetic Resonance
Imaging (MRI) (no sign of white matter lesion or atro-
phy). Finally, given a putative role of LC and noradrena-
line in cognition and mood (including depression) we
excluded from this study patients with a positive score
at UPDRS part I.
A quantitative profile of each patient’ motor impair-
ment was obtained from clinical assessment performed
before SPECT by means of the UPDRS motor part (part
III). L-Dopa daily dose and L-Dopa Equivalent Daily
Doses (LEDDs) were also recorded, with the latter
expressed as follows: 100 mg levodopa = 1.5 mg prami-
pexole = 6 mg ropinirole. None of the subjects (both
PD and HC) were taking or stated to have ever been
treated with antipsychotics or drugs known to affect the
noradrenergic system (e.g., noradrenaline reuptake inhi-
bitors). Drug naïve patients at the time of SPECT were
not included in the study. The Ethics Committee of the
Department of Human Physiology approved the study
and all subjects gave informed consent.
SPECT data acquisition and processing
Intravenous administration of 110-140 MBq of FP-CIT
(DaTSCAN, GE-Healthcare, UK) was performed 30-40
minutes after thyroid blockade (10-15 mg of Lugol oral
solution) in the control subjects and in patients after
overnight withdrawal of dopaminergic therapy [15].
Brain SPECT was performed 3 hours later by means of
a dedicated triple detector gamma-camera (Prism 3000,
Philips, Eindhoven, the Netherlands) equipped with low-
energy ultra-high resolution fan beam collimators (4
subsets of acquisitions, matrix size 128x128, radius of
rotation 12.9-13.9 cm, continuous rotation, angular sam-
pling: 3 degree, duration: 28 minutes). Brain sections
were reconstructed with an iterative algorithm (OSEM,
4 iterations and 15 subsets) and then processed by 3D
filtering (Butterworth, 5th order, cut-off 0.31 pixel-1) and
attenuation correction (Chang method, factor 0.12).
Imaging data analysis
Two different and complementary image analyses were
performed: a voxel-based whole brain analysis using Sta-
tistical Parametric Mapping SPM2 (Wellcome Depart-
ment of Imaging Neuroscience, London, UK)
implemented in MATLAB R2007a (The Mathworks Inc,
USA), and a volume of interest (VOI) analysis of a
priori defined brain regions.
SPM analysis
A group-specific FP-CIT template was created by (i)
spatially normalizing the FP-CIT images of 15 healthy
subjects onto a FP-CIT MNI-based template, [16] (ii)
subsequent averaging of the normalized images and
their symmetric (mirror) images resulting in a mean
image, and finally (iii) a smoothing of the mean image
using a 3-dimensional Gaussian kernel with 8-mm full
width at half maximum (FWHM). To increase the sig-
nal-to-noise ratio and account for subtle variations in
anatomic structures, the individual subject’s FP-CIT
images were spatially normalized to this group-specific
template and smoothed with a FWHM 10-mm Gaussian
kernel. A reference region in the occipital cortex was
defined as the union of the superior, middle and inferior
occipital gyri along with the calcarine gyri VOIs defined
by automated anatomical labelling (AAL), using the
Wake Forest University (WFU) PickAtlas 2.4 software.
Binding values for each subject’s FP-CIT image were
then computed in a voxel-by-voxel manner (voxel -
occipital reference)/(occipital reference). Using the
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General Linear Model in voxel-based statistical analysis
of SPM2, a two-sample t-test contrast was used to eluci-
date group difference between PD and HC. No global
normalization, or grand mean scaling, were applied, and
the masking threshold was set to zero. Clusters of at
least 35 voxels with the height threshold set at p <
0.001, were considered significant.
VOI analysis
The LC FP-CIT binding values were for two VOIs (for
left and right part of LC) created, using WFU Pick Atlas
Tool, through the union of six distinct, contiguous
Boxes (of 3 mm on the z axis for each side), centered in
the mean values on the x and y axis and dimensioned
according to the standard deviation as proposed in
Table 1 of Keren and coll., 2009 [17]. FP-CIT binding
values for the caudate nucleus (CN) and putamen (PT)
were calculated on the basis of VOIs defined with the
Basal Ganglia Matching Tool [18]. Student’s t-test was
then applied. We defined as contralateral, those brain
regions opposite to that of PD most severe sign presen-
tation. For HC, we referred to the right side as ipsilat-
eral [15].
General statistical analysis
Unless otherwise stated, data are reported as median
and range. Normality of data distribution was tested
by means of Shapiro-Wilks test. Chi-Square was used
to test gender distribution among groups. Demo-
graphic data were compared by means of Wilcoxon
two-group test. The Spearman correlation coefficient
was calculated to investigate statistical dependence
among average binding values, demographic and clini-
cal variables.
Statistical analyses were performed with the JMP sta-
tistical package, version 8.0 (SAS Institute, Inc., Cary,
NC, USA).
Results
Table 1 shows the demographic and clinical characteris-
tics of the study cohorts.
SPM analysis detected one large cluster of 6819 voxels
(peaks at coordinates: 28 -8 -4 and at -31 -8 -4) of sig-
nificantly reduced FP-CIT binding involving the PT and
the CN bilaterally (Figure 1, left). A cluster of 37 voxels
(peak at coordinates: 2 -36 -26) with higher FP-CIT
binding values was found in the LC of PD subjects (Fig-
ure 1, right).
Volumes of interest analysis revealed reduced average
binding values in the striatum and increased average
binding value in LC area, bilaterally (Table 2).
FP-CIT binding in the striatum showed a weak, but
significant, negative correlation with binding values of
the corresponding LC (caudate: contralateral, r = -0.28,
p = 0.004 and ipsilateral r = -0.26, p = 0.008; putamen:
contralateral, r = -0.29, p = 0.004 and ipsilateral r =
-0.29, p = 0.003) (Figure 2). LC binding did not show
other significant correlations. Finally, results for the FP-
CIT binding value in the LC area proved to be statisti-
cally independent when weighted for demographic (age
at SPECT, age at onset, gender) and clinical characteris-
tics (disease duration, disease severity and L-Dopa daily
dose and LEDDs).
Discussion
Increased FP-CIT binding in the LC area
The present study provides in vivo evidence of higher
baseline catecholamine transporter binding in the LC
region in a large and homogeneous cohort of subjects
with early PD. Our findings are consistent with an up-
regulation of noradrenaline reuptake in the LC area,
which is well compatible with enhanced noradrenaline
release [19,20].
Our results are derived from the analysis of the bind-
ing of FP-CIT, a 123I-labeled cocaine derivative with
high affinity for dopamine (DAT; KD = 2nM) and a les-
ser affinity towards noradrenaline transporter (NET; KD
= 140 nM) [14]. Despite the higher affinity of FP-CIT
for DATs, it is unlikely that the higher binding observed
in the LC area is due to an enhanced dopaminergic,
rather than noradrenergic, transporter for two main rea-
sons: (i) in LC, DAT represent a minor and inconsistent
component of the midbrain-derived dopaminergic term-
inals which degenerates in PD, along with other dopa-
minergic projections, [4] and (ii) in the LC a major NET
component is synthesized in the cell body of pigmented
neurons and exposed on their membrane to be trans-
ferred toward axonal terminals, [20] with a less
Table 1 Demographics and clinical data
PD HC
Subjects N. (male/female) 94 (67/27) 15 (4/11)*
Age at SPECT 60 (38 - 75) 63 (51 -
74)
Age at motor symptoms onset 57 (37 - 72)
Disease duration 3 (1 - 5)
UPDRS motor score (part-III) [range 0 -
108]
19 (8 - 56)
Hoehn and Yahr stage [range 1 - 5] 2 (1 - 2)
L-Dopa in mg/day 400 (0 - 850)
LEDDs in mg/day 250 (70 -
1200)
Data are reported as median and range (brackets). Age at SPECT, age at
motor symptoms onset and disease duration are in years. All patients were
evaluated with the Unified Parkinson Disease Rating Scale motor part (UPDRS
part III) in drugs-off state (i.e. after overnight withdrawal of specific drugs for
PD, no patients was taking long-acting dopaminergic drugs). LEDDs were
calculated as follow: 100 mg levodopa = 1.5 mg pramipexole = 6 mg
ropinirole. * p = 0.0005.
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consistent NET component localized on terminal pro-
jections arising from more caudal noradrenergic cell
groups [21].
In PD, reduced dopamine release from nigro-striatal
projections results in loss and adaptive down-regulation
of DAT binding sites in the striatal region [22]. In line
with this notion, and in agreement with studies in de
novo and early PD, where 40 to 60% of nigral dopami-
nergic neurons are lost, [15,23] we found a significantly
reduced FP-CIT binding in the caudate and putamen of
PD patients. In contrast to the striatal compartment,
analysis of FP-CIT labeling in the upper brainstem
revealed significantly increased binding in a pontine area
adjacent to the floor of the fourth ventricle and extend-
ing into the midbrain to the level of the inferior
colliculi. This area corresponds topographically to the
LC coordinates identified by other studies including
those employing neuromelanin-sensitive MRI methods
[6,17,24,25]. In addition, the LC is the sole structure in
the posterior rostral pons housing monoamine transpor-
ters [1], thus further supporting our claim of anatomical
targeting of the LC.
Only two prior studies with PET have specifically
investigated the LC in PD patients. A first, [24] reported
a reduced 18F-dopa intake in patients with advanced PD
when compared to patients at an early stage of the dis-
ease. Because 18F-dopa intake is more specifically related
to dopaminergic neurotransmission, this study does not
provide information on noradrenergic functioning of
LC. In a second study, [6] PD subjects with depression
showed a reduced binding of [11C]RTI-32, a marker of
both DAT and NET, when compared to non-depressed
patients. Interestingly, the noradrenergic activity of early
non-depressed PD patients was within normal range in
most patients and enhanced in few of them. In line with
these findings, and having enrolled a larger and more
selected cohort of subjects, we were able to reveal a sig-
nificantly higher LC activity at an early stage of PD for
the first time.
An acute effect of drugs on FP-CIT binding values
appears unlikely since SPECT was performed after over-
night withdrawal of anti-parkinsonian drugs. In addition,
in animal studies, systemic administration of D2/D3
receptor agonists, such as pramipexole or apomorphine,
showed little or no effect on the firing rate of LC-NA
neurons [26]. Finally, a persistent treatment with
Figure 1 Overlay on a MRI showing the loss of FP-CIT binding bilaterally in the striatum (cluster of 6819 voxels, peaks at coordinates:
28 -8 -4 and at -31 -8 -4) (left in the figure) and increased FP-CIT binding in the locus coeruleus area (cluster of 37 voxels, peak at
coordinates: 2 -36 -26) (right in the figure) of the whole group of PD patients compared to controls.
Table 2 Binding values obtained with the analysis of
volumes of interest
Region of interest PD HC p values
CN contralateral 3.18 (1.2 - 3.84) 5.27 (3.51 - 6.15) < 0.0001
CN ipsilateral 3.29 (0.98 - 6.26) 5.27 (3.51 - 6.6) < 0.0001
PT contralateral 1.86 (0.65 - 4.72) 4.83 (3.07 - 6.04) < 0.0001
PT ipsilateral 1.97 (0.76 - 4.65) 4.83 (3.62 - 6.37) < 0.0001
LC contralateral 313.5 (81 - 663) 131.43 (59 - 371) 0.001
LC ipsilateral 321.17 (87 - 632) 123.6 (38 - 354) 0.0004
Data are reported as median and range (brackets). Average FP-CIT binding in
the caudate nucleus (CN) and putamen (PT) was significantly reduced in
subjects with PD subjects compared to HC. On the contrary, PD patients
showed a significantly increased binding in the LC area (both right and left
regions). We defined contralateral brain regions opposite to that of PD signs
presentation. For HC, we referred to the right side as ipsilateral [15].
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dopaminergic drugs will eventually down-regulate,
rather than up-regulate, the surface expression of DAT
and NET through internalization of the transporters
[27,28]. Accordingly, the average FP-CIT binding values
in the LC remained enhanced when data were L-Dopa
weighted for equivalent daily dose and L-Dopa daily
dose.
In vivo versus anatomopathological studies
Enhanced noradrenergic binding, and possibly activity,
in PD might be considered at odds with neuropathologi-
cal findings, where frank neuronal degeneration has
been recognized within LC, based on detection of speci-
fic cellular markers. Indeed, morphologic hallmarks of
sporadic PD (Lewy bodies and dystrophic neurites con-
taining pathologic a-synuclein) may appear initially in
the lower brainstem [2].
However, Lewy pathology can correlate poorly with
neuronal loss in specific areas, thus its validity in pre-
dicting neuronal disintegration is questionable [29]. In
fact, noradrenergic neurons in the LC are relatively pre-
served in early PD and do not exhibit the same intracel-
lular changes as in the substantia nigra [30].
Accordingly, neuromelanin-sensitive imaging methods
in vivo, [25] as well as anatomopathological studies sug-
gested that the loss of NA neurons in PD may be con-
fined to the larger, pigmented cells localized in the
caudal part of the nucleus, whereas small unpigmented
cells are increased in number, as if derived from shrink-
age of larger neurons [31].
However, available information on the LC, so far
derived from anatomopathological studies in subjects
with PD, is poorly comparable with our findings. In par-
ticular, the limited number of PD subjects investigated
and the lack of clinical information (e.g. disease duration
and the presence of depression or cognitive impairment)
of patients in anatomopathological studies prevent a
direct comparison between these studies and our results
[31,32].
Implications of enhanced LC-NA functioning in PD at an
early stage
Based on anatomical and histochemical data, along with
neuropharmacological evidence, higher activity of the
LC in PD may suggest: (i) in the striatum, noradrenaline
plays a compensatory role cross targeting dopaminergic
receptors (synaptic action); while (ii) in the substantia
nigra, noradrenaline has a neuroprotective bolstering
dopaminergic cells (extra-synaptic paracrine action).
As for the compensatory role, there is no absolute
specificity for catecholaminergic substrate-receptor
interactions, implying that one catecholamine can cross-
talk with the pharmacologically defined receptors or
transporters belonging to other catecholamines. Indeed,
noradrenaline binds to pharmacologically defined dopa-
minergic receptors [11,33,34]. Therefore, enhanced
Figure 2 Scatter plots and linear correlations of ipsilateral (left in the figure) and contralateral (right in the figure) FP-CIT binding
values of the locus coeruleus and striatum (caudate nucleus and putamen). A statistically significant negative correlation was found
between FP-CIT binding values in the locus coeruleus area and the corresponding striatum (both caudate nucleus and putamen).
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noradrenaline release may be able to partially compen-
sate a dopaminergic innervation loss due to degenera-
tion of the substantia nigra.
With reference to a putative neuroprotective activity,
noradrenaline suppresses pro-inflammatory and ele-
vates anti-inflammatory molecules [35] and has the
ability to scavenge superoxide and reactive oxygen spe-
cies, which are thought to contribute to cellular
damage and dopaminergic cell death [36]. Further-
more, the tottering mouse, which has noradrenergic
hyperinnervation and increased levels of noradrenaline
throughout the forebrain, appears to be protected from
MPTP toxicity [37] while MPTP-induced damage to
nigrostriatal dopaminergic neurons was potentiated by
pretreatment with DSP-4, a selective LC neurotoxin
[38]. Therefore, we speculate that enhanced LC-NA
may be regarded as an endogenous paracrine agent
promoting dopaminergic neuron survival [39,40]. This
hypothesis would predict that degeneration of LC nor-
adrenergic neurons in later stages of the disease might
accelerate degeneration of substantia nigra dopaminer-
gic neurons. The negative correlation between FP-CIT
binding in the striatum and LC area is consistent with
the above considerations of LC-NA compensatory and
protective activity.
Conclusions
The present study suggests higher baseline catechola-
mine transporter binding in the LC area of patients with
early stage PD. We propose that enhanced noradrener-
gic activity may be one factor modulating the severity of
motor symptoms and may even influence progression of
dopaminergic neurodegeneration.
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In this second study we attempted to investigate the correlation between LC-NAergic activity and 
Parkinson tremor.  
Tremor activity was recorded in 12 consecutive PD subjects during a specific task (A-V200, see 
below) activating the LC. The intensity of tremor (i.e., the power of EMG signals), but not its 
frequency, significantly increased during the task in all patients. In six subjects, tremor appeared 
selectively during the task (see article Figure 1 [also below] and Table 3).  
In a second part of the study, we compared DAT binding values (investigated by means of SPECT 
and FP-CIT) of PD subjects with bilateral tremor (n = 27), unilateral tremor (n = 22), and no tremor 
(n = 33) (see article Table 2) and confirmed in an ample homogeneous study population the lack of 
a direct correlation between DAergic innervation loss and Parkinson tremor (Isaias et al., 2007). 
The present study provides preliminary evidence of a LC-related activity in the generation of 
tremor in PD.  
Relatively few neuroimaging studies in human (and none in PD patients) described an activation 
of LC (Coull et al., 1999; Sturm et al., 1999; Tracy et al., 2000; Knutson et al., 2000; Dunckley et al., 
2005; Liddell et al., 2005; Sterpenich et al., 2006). Amongst these studies, several activated the LC 
using stress of various sorts, such as aversive loud noises (Tracy et al. 2000), monetary punishment 
(Knutson et al. 2000), pain stimuli (Dunckley et al. 2005), facial expressions of fear (Liddell et al., 
2005) and emotionally aversive images such as snakes (Sterpenich et al. 2006). Sturm et al. (1999) 
used a non-specific but also non-aversive alertness task, in which subjects had to respond rapidly 
with a key-press every time a light was flashed. Coull et al., (1999) used a drug test showing that 
the α2-receptor agonist clonidine impaired subjects’ performance of an attentional task (rapid serial 
visual presentation, or RSVP) and suppressed resting state LC activation, probably via stimulating 
inhibitory α2-autoreceptors in LC neurons. Regarding this last study it is worth mentioning that 
the effects of drugs on the LC depend both on dosage and on the subjects’ arousal level (Arnsten, 
2006). Moreover, they affect the activation not only of NA’s source (the LC), but also of the 
transmitter’s targets, including many cortical areas such as prefrontal and parietal, and also 
different transmitter systems such as that of dopamine (from Pan et al., 2004). Accordingly, the use 
of a NAergic drug guarantees neither that the LC will be activated, nor that observed brainstem 
activation must have the LC as its source. Among the many tasks activating the LC, the most easily 
applicable in a laboratory setting to obtain preliminary data for further brain imaging studies (e.g. 
fMRI or PET) was the challenge-driven attention task proposed by Raizada and Poldrack (Raizada 
and Poldrack, 2008). This task consist of an audio-visual simultaneity detection (A-V, see Raizada 
and Poldrack, 2008) in which subjects are presented with a flashed white disc and a burst of noise, 
their task being to decide whether the visual and the auditory stimuli were perceived, 
simultaneously or apart. In our study, a total of 50 visual and auditory stimuli were presented, 10–
15 of them, in random order, delivered apart. The stimulus onset asynchrony between the visual 
and the auditory stimuli was set at 200 ms (A-V200), 100 ms (A-V100) or 0 ms (A-Vnull) in three 
separate trials. The A-V200 task demonstrated to specifically activate the brainstem and possibly 
the LC-NA system. Whereas, the A-V100 and the A-Vnull task did not appear to elicit a brainstem 
response and served as control tasks (see Figure 2 in Raizada and Poldrack, 2008). Inter-stimuli 
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time (i.e., the time between a paired audio-visual stimulus and the following one) ranged 
randomly between 2.5 and 7 s. Each task was interpolated between a pre- (90 s) and a post-task 
period (up to epoch completion), with no audio-visual input. Trials were randomized for all 
patients. At the beginning of the experimental session, tremor activity was recorded for 60 s at rest 
and with no audio-visual input. 
 
 
 
 
Figure 1 in Isaias et al., Front Hum Neurosci. 2011;5:179 (see article for description).  
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We analyzed rest tremor, one of the etiologically most elusive hallmarks of Parkinson
disease (PD), in 12 consecutive PD patients during a specific task activating the locus
coeruleus (LC) to investigate a putative role of noradrenaline (NA) in tremor generation and
suppression. Clinical diagnosiswas confirmed in all subjects by reduceddopamine reuptake
transporter (DAT) binding values investigated by single photon computed tomography
imaging (SPECT) with [123I] N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) tropane
(FP-CIT). The intensity of tremor (i.e., the power of Electromyography [EMG] signals), but
not its frequency, significantly increased during the task. In six subjects, tremor appeared
selectively during the task. In a second part of the study, we retrospectively reviewed
SPECT with FP-CIT data and confirmed the lack of correlation between dopaminergic loss
and tremor by comparing DAT binding values of 82 PD subjects with bilateral tremor
(n = 27), unilateral tremor (n = 22), and no tremor (n = 33). This study suggests a role of
the LC in Parkinson tremor.
Keywords: Parkinson disease, tremor, locus coeruleus, noradrenaline
INTRODUCTION
Tremor in Parkinson disease (PD) is characterized by 4–6Hz
activity at rest in the limbs with distal predominance. Despite its
clinical importance and the burden of morbidity associated with
it, the etiology of tremor is unknown, and its medical treatment
commonly ineffective.
The tremor in PD is remarkable for several features: (1) it is
neither a consistent nor a homogeneous feature across patients or
within an individual patient’s disease course; (2) it may diminish
in the end-stage of PD; (3) it occurs predominantly at rest and is
reduced or disappears by action; (4) it increases in amplitude or
can be triggered by maneuvers such as walking or psychological
states as anxiety or stress (specific tasks, like simple arithmetic cal-
culation, may induce stress-related tremor) (Deuschl et al., 1998);
(5) it is not present during sleep; (6) it may be the predominant
or the only clinical sign for years before the appearance of aki-
nesia (Brooks et al., 1992); and (7) it poorly correlates with the
nigrostriatal dopaminergic deficits (Isaias et al., 2007).
Although there is converging evidence of independent oscil-
lating circuits within a widespread “tremor-generating network”
(Mure et al., 2011), there is no conclusive explanation for the
onset of tremor in what it is fundamentally a hypokinetic move-
ment disorder.
Our hypothesis is that the locus coeruleus (LC) is involved in
the generation of tremor in PD. Preliminary evidence of a role
of adrenaline and noradrenaline (NA) in parkinsonian tremor
emerged from studies published in the 1960s and 1980s (Constas,
1962; Colpaert, 1987; Wilbur et al., 1988).
In this study we applied a specific and selective task activat-
ing the LC (Raizada and Poldrack, 2008), the main source of NA
in the brain, while recording tremor in 12 consecutive subjects
with PD.
In a second part of the study, we confirmed retrospectively,
in a large and homogeneous cohort of PD subjects with and
without tremor, the lack of correlation between tremor and
dopaminergic innervation loss, investigated by means of sin-
gle photon computed tomography imaging (SPECT) with [123I]
N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) tropane
(FP-CIT) (Isaias et al., 2007).
MATERIALS AND METHODS
PATIENTS AND CLINICAL ASSESSMENT
The diagnosis of PD was made in all subjects according to the
UK Parkinson Disease Brain Bank criteria and patients were eval-
uated by means of the Unified Parkinson Disease Rating Scale
motor part (UPDRS-III). Two additional UPDRS subscores (i.e.,
a tremor subscore and an akinetic-rigid (AK) subscore) were also
calculated (Isaias et al., 2007). L-Dopa Equivalent Daily Doses
(LEDDs) were recorded as follows: 100mg levodopa = 1.5mg
pramipexole= 6mg ropinirole.
Clinical inclusion criteria were: (1) UPDRS part I and IV of 0;
(2) Hoehn and Yahr (H&Y) stage of 1 or 2 in drugs-off state at the
time of SPECT (i.e., after overnight withdrawal of specific drugs
for PD; no patient was taking long-acting dopaminergic drugs);
(3) absence of any sign indicative for atypical parkinsonism (e.g.,
gaze abnormalities, autonomic dysfunction, and significant psy-
chiatric disturbances) over a follow-up time of at least three
years after symptoms onset; (4) positive clinical improvement at
UPDRS after L-Dopa intake (i.e., >30% from drug-off state) at
some point during the three years of follow-up; (5) a normal
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Magnetic Resonance Imaging (MRI) (no sign of white matter
lesion or atrophy).
Additional inclusion criteria for the 12 consecutive patients
who took part to the prospective study were: (1) no other
disease other than PD; (2) no therapy change for the past
six months prior to the study; only patients with L-Dopa
or dopamine agonist were recruited and the uptake of any
drugs affecting the noradrenergic system (including, β-blockers,
MAO-B inhibitors, etc.,) was ruled out; (3) no cognitive decline
as well as no deficit in visual attention. All subjects had normal
scores at the Mini-Mental State examination, the Clock Drawing
Test, the Frontal Assessment Battery, the Rey Auditory Verbal
Learning Test; the Digit SpanTest, and the Attentive Matrices Test.
Depression was also ruled out by means of the Beck Depression
Inventory.
Fifteen healthy controls (four males, 11 female; 63 years
on average ±9 SD; range: 51–74 years) were prospectively
enrolled for comparisons of FP-CIT uptake. Healthy controls
were recruited from the general population (relatives of patients
were excluded) and, at the time of the study, did not suffer from
any disease and were not taking any medication.
The Local Ethics Committee approved the study and all sub-
jects gave their informed consent.
IMAGING
Dopamine-transporter (DAT) values were measured by means of
SPECT with [123I] FP-CIT.
SPECT data acquisition and reconstruction has been described
in details elsewhere (Isaias et al., 2010). In brief, intravenous
administration of 110–140MBq of FP-CIT (DaTSCAN, GE-
Healthcare, UK) was performed 30–40min after thyroid blockade
(10–15mg of Lugol oral solution) in subjects with PD subse-
quently overnight withdrawal of dopaminergic therapy and in
healthy controls. Brain SPECT was performed three hours later
by means of a dedicated triple detector gamma-camera (Prism
3000, Philips, Eindhoven, The Netherlands) equipped with low-
energy ultra-high resolution fan beam collimators (four sub-
sets of acquisitions, matrix size 128× 128, radius of rotation
12.9–13.9 cm, continuous rotation, angular sampling: 3 degree,
duration: 28min). Brain sections were reconstructed with an
iterative algorithm Ordered Subsets Expectation Maximization
(OSEM, four iterations and 15 subsets) and then processed by
3D filtering (Butterworth, order 5, cut-off 0.31 pixel-1) and
attenuation correction (Chang method, factor 0.12).
FP-CIT uptake values for the caudate nucleus and putamen of
both PD patients and healthy controls were calculated according
to Basal Ganglia Matching Tool (Calvini et al., 2007). The FP-CIT
uptake values in other brain regions were obtained with the cre-
ation, in the shapes menu of WFU Pick Atlas Tool, of specific
volumes of interest (VOIs).
Contralateral refers to the side opposite to tremor or to the
most affected side. For healthy controls we referred to the right
side as ipsilateral (Isaias et al., 2007).
AUDIO-VISUAL TASK AND EXPERIMENTAL DESIGN
We used the task of audio-visual simultaneity detection (A-V,
Raizada and Poldrack, 2008) in which subjects were presented
with a flashed white disc and a burst of noise, their task being to
decide whether the visual and the auditory stimuli were perceived,
simultaneously or apart. A total of 50 visual and auditory stimuli
were presented, 10–15 of them, in random order, delivered apart.
The stimulus onset asynchrony between the visual and the audi-
tory stimuli was set at 200ms (A-V200), 100ms (A-V100) or 0ms
(A-Vnull) in three separate trials. The A-V200 task demonstrated
to specifically activate the LC-NA system. The A-V100 and the
A-Vnull task did not appear to elicit a brainstem response and
served as control tasks (Raizada and Poldrack, 2008). Inter-
stimuli time (i.e., the time between a paired audio-visual stimulus
and the following one) ranged randomly between 2.5 and 7 s.
Each task was interpolated between a pre- (90 s) and a post-task
period (up to epoch completion), with no audio-visual input.
Trials were randomized for all patients. At the beginning of the
experimental session, tremor activity was recorded for 60 s at rest
and with no audio-visual input.
RECORDINGS
Muscle activity was registered with surface Electromyography
(EMG) electrodes placed on the extensor digitorum communis
(EDC), the flexor digitorum communis (FDC), and the opponens
pollicis (OP) muscles, bilaterally. To include only EMG bursting
activity, the EMG was high-pass filtered off-line at 60Hz and rec-
tified (Timmermann et al., 2003). Recordings were performed
during rest and during the audio-visual task while the subjects
relaxed their arm and hand muscles. The examination was per-
formed at the same day-time (10:00 h) for all patients. Patients
were asked not to drink alcoholic, caffeine, or tea from the evening
before the examination and they were off any medication in the
last three days before the task. The examination was performed
in a quiet room after allowing enough time for the patients to
become familiar with the surroundings.
GENERAL STATISTICAL ANALYSIS
Tremor frequency and intensity were compared by use of the
Wilcoxon signed-rank test for matched pairs. A pair was the same
individual but at a different time during the task (e.g., pre-task vs.
task). Student’s t-test was applied to compare DAT binding values
among patient sub-groups and healthy controls. Statistical analy-
ses were performed with the JMP statistical package, version 8.0.2
(SAS Institute, Inc., Cary, NC, USA).
RESULTS
Demographic and clinical features are listed in Table 1A for all
subjects with PD and further detailed in Table 1B for the 12
patients who performed the audio-visual tasks.
Table 2 lists DAT binding values. All 12 subjects enrolled for
the EMG recording showed a reduced DAT binding value in the
striatum (12% and 22% in the ipsilateral and contralateral cau-
date nucleus; 41% and 53% in the ipsilateral and contralateral
putamen), thus further confirming the clinical diagnosis. DAT
binding values did not differ between PD subjects with and with-
out tremor in all regions investigated, also when weighted for
demographic (age at SPECT, age at onset, gender) and clinical
data (disease duration, disease severity, and LEDDs). Of interest,
DAT binding values in the pons (where the LC is located) resulted
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Table 1 | Clinical and demographic characteristics of the 82 subjects with PD (A) and of the 12 patients enrolled for the audio-visual task (B).
Table 1A
Bilateral tremor (n = 27; 21M) On-side tremor (n = 22; 16M) No tremor (n = 33; 22M)
Age at onset (years) 54± 11 58± 8 55± 8
Disease duration (years) 8± 5 5± 3 7± 5
UPDRS-III (0–108) score 23± 10 17± 7.4 18.7± 9.7
UPDRS-tremor (0–28) score 5.2± 2.5 2± 0.8 0
UPDRS-AK (0–48) score 9.3± 5 6.6± 3.5 10.2± 6.6
LEDDs (mg) 424.6± 270 356.5± 256.1 506.0± 282.1
Table 1B
Patient Sex Age Disease H&Y UPDRS III—tremor UPDRS III—item 22 UPDRS III LEDDs (mg)
duration score left/right left/right (AK score) total score
1 M 64 18 2 3/2 2/2 (13) 28 560
2 M 73 10 2 3/0 2/2 (11) 27 510
3 M 56 10 2 2/0 1/0 (7) 20 710
4 M 70 5 2 0/2 1/2 (5) 12 580
5 F 71 4 2 0/2 2/1 (5) 13 610
6 M 73 4 2 3/0 2/0 (5) 19 300
7 M 58 12 2 3/1 2/2 (8) 16 210
8 M 70 4 2 3/0 2/0 (8) 24 480
9 M 69 9 2 0/3 2/2 (11) 23 400
10 F 76 3 2 3/1 2/2 (11) 22 300
11 M 69 6 2 2/0 2/2 (5) 12 255
12 M 65 7 2 0/1 2/2 (9) 18 450
Each patient’s disease severity was assessed using the Hoehn and Yahr (H&Y maximum is 5) stages and the Unified Parkinson Disease Rating Scale part III (UPDRS-
III; maximum score is 108). UPDRS item 20 and 21 refer to rest and action or postural tremor; item 22 refers to rigidity. UPDRS akinetic-rigid (AK) score was the sum
of items: 18 (speech), 19 (facial expression), 22 (rigidity), 27 (arising from chair), 28 (posture), 29 (gait), 30 (postural stability), 31 (body bradykinesia); tremor score
was the sum of items: 20 (tremor at rest), and 21 (action or postural tremor of hands). L-Dopa Equivalent Daily Doses (LEDDs) were recorded as follows: 100mg
levodopa = 1.5mg pramipexole = 6mg ropinirole. In Table 1A, values are means ± SD. See text for inclusion criteria.
significantly higher in PD patients with tremor when compared to
healthy controls. Still, no difference was found between PD with
and without tremor within this region.
All 12 patients showed the typical parkinsonian rest tremor
in the frequency range of 4–6Hz. No changes in tremor fre-
quency or intensity were found during A-V100 and A-Vnull. On
the contrary, tremor intensity greatly and consistently increased
during the A-V200 task in all patients (p < 0.001) (Table 3).
Interestingly, tremor frequency during the same task did not
significantly change (Table 3, first column). The figure illus-
trates tremor behavior in one patient during one trial with the
A-V200 task (n. 4 in Table 3). Note that EMG activity of left EDC
(Figure 1, mid box) appears only during the audio-visual task.
Interestingly, the power spectral analysis (Figure 1, lower box)
clearly describes, during the audio-visual task, an enhancement of
tremor intensity and a sustained 4.2Hz tremor frequency. Similar
results were found in all other PD subjects (Table 3).
DISCUSSION
The present study suggests a LC-related activity in the generation
of tremor in PD. We also confirmed in an ample homogeneous
study population the lack of a correlation between dopaminergic
innervation loss and parkinsonian tremor (Isaias et al., 2007).
There is increasing evidence that resting tremor in PD is asso-
ciated with a distinct cerebello-thalamic circuit involving the ven-
tral intermediate nucleus of the thalamus (Vim), the cerebellum,
and the motor cortex. Indeed, a distinct ponto-thalamo-cortical
pattern, possibly involving the cerebellum/dentate nucleus, the
primary motor cortex, and the caudate/putamen have been iden-
tified in tremor-predominant PD patients (Mure et al., 2011).
More recently, a selective dopaminergic depletion of the globus
pallidus (but not striatum) has been reported to correlate with
clinical tremor severity and suggested to link the basal ganglia
with the cerebello-thalamic circuit in the onset of rest tremor
in PD (Helmich et al., 2011). We failed to find any difference
of dopamine innervation loss (including the globus pallidus)
between PD subjects with bilateral, unilateral, or without tremor.
Indeed, structural lesions of the substantia nigra produce akinetic
syndromes but not tremor (Jenner and Marsden, 1984). The role
of the cerebellum has been also questioned by a multi-tracer PET
study showing that at least part of the cerebellar hyperactivation
seen in tremulous PD might be related to akinesia and rigidity
(Ghaemi et al., 2002). The development of rest tremor associated
with PD in a patient who had prior cerebellectomy further sug-
gested that the cerebellum is not the primary origin of tremor
(Deuschl et al., 1999).
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Table 2 | FP-CIT SPECT binding values.
Bilateral tremor One-side tremor No tremor Healthy controls
(n = 27) (right n = 11; left n = 11) (n = 33) (n = 15)
Frontal lobe 0.11±0.08 0.07±0.11 0.11±0.09 0.06±0.08
Cerebellum 0.12±0.07∗∗ 0.12±0.06∗∗ 0.11±0.09∗∗ 0.05±0.04
Pons 0.54±0.13∗ 0.53±0.11∗ 0.49±0.21 0.42±0.14
Brainstem 1.52±1.32 1.97±2.14∗∗ 1.85±1.48∗∗ 0.54±0.13
Midbrain 0.67±0.16 0.69±0.13 0.63±0.21 0.69±0.15
Thalamus contralateral 0.55±0.14 0.57±0.19 0.52±0.19 0.6±0.13
Thalamus ipsilateral 0.57±0.14 0.6±0.15 0.55±0.16 0.59±0.17
GPe contralateral 1.32±0.33∗∗ 1.31±0.26∗∗ 1.22±0.42∗∗ 2±0.32
GPe ipsilateral 1.32±0.39∗∗ 1.49±0.28∗∗ 1.3±0.42∗∗ 2.2±0.32
GPi contralateral 1.22±0.28∗∗ 1.21±0.24∗∗ 1.13±0.34∗∗ 1.6±0.33
GPi ipsilateral 1.21±0.32∗∗ 1.32±0.23∗∗ 1.19±0.33∗∗ 1.76± 0.28
Caudate contralateral 3.14±1.02∗∗ 3.17±0.81∗∗ 3±0.94∗∗ 4.95±0.98
Caudate ipsilateral 3±0.89∗∗ 3.65±0.85∗∗ 3±0.97∗∗ 4.94±0.96
Putamen contralateral 2±0.73∗∗ 2±0.59∗∗ 2±0.86∗∗ 4.6±0.83
Putamen ipsilateral 2.17±0.75∗∗ 2.5±0.64∗∗ 2.22±0.87∗∗ 4.6±0.83
Data are shown as means ± SD (with the bilateral occipital cortex as reference region). Contralateral refers to the side opposite to tremor or to the most affected
side for patients without tremor. For healthy subjects, we conventionally referred to the right side as ipsilateral. For the one-side tremor group, the ipsilateral brain
regions refer to the hemisoma without rest or postural tremor. The absence of tremor (bilaterally or unilaterally) derived by a UPDRS-III score of 0 at the previous
visit (within two months) before SPECT and by the anamnestic statement by the patient of having not experienced tremor (bilaterally or at the non-tremor side).
FP-CIT uptake values for the caudate nucleus and putamen were calculated according to Basal Ganglia Matching Tool. The FP-CIT uptake values in other brain
regions were obtained with the creation, in the shapes menu of WFU Pick Atlas Tool, of specific volumes of interest (VOIs).
DAT binding values did not differ among PD sub-groups (with or without tremor), also when weighted for demographic (age at SPECT, age at onset, gender) and
clinical data (disease duration, disease severity, and LEDDs). Therefore, statistical significance is marked only vs. healthy controls.
∗p = 0.01; ∗∗p < 0.001.
GPe = globus pallidus pars externa; GPi = globus pallidus pars interna.
Table 3 | Changes of tremor intensity (i.e., power of EMG signals) during the audio-visual task.
Patient Muscle fPEAK (fAVG) Pre-task (0–90s) A-V200 task (90s–EoT) Post-task early (EoT–400 s) Post-task late (400–500 s)
PPEAK (PAVG) PPEAK (PAVG) PPEAK (PAVG) PPEAK (PAVG)
1 R-flex 4.8 (4.6) 83 (50) 4250 (1118) 1975 (296) −
2 R-flex 4.9 (4.9) − 14,130 (1405) 9834 (2704) 1703 (376)
3 L-ext 5.8 (5.8) 380 (181) 1755 (912) 349 (260) 265 (70)
4 L-ext 4.2 (4.2) − 800 (296) 266 (100) −
5 R-ext 4.9 (5.1) 2686 (819) 8022 (2240) 3686 (501) −
6 L-opp 3.9 (3.9) − 14,759 (4286) − −
7 L-flex 4.9 (4.9) − 9563 (2937) 4314 (1552) −
8 L-flex 4.2 (4.2) − 7393 (838) − −
9 R-opp 4.3 (4.2) 1981 (719) 8806 (2963) 1222 (231) −
10 L-ext 5.5 (5.3) − 1244 (86) 145 (35) 109 (41)
11 L-opp 3.9 (3.9) − 2907 (267) − −
12 R-opp 3.5 (3.5) − 135 (56) − −
Pre-task refers to a period of 90 s without stimuli preceding the audio-visual task (A-V200). Post-task early refers to the first time period without stimuli after the task
end (from End-of-Task (EoT) to 400 s counting from the start of the EMG recording); post-task late refers to the last part of the period without stimuli (from 400 to
the end of EMG recording). We listed only the activity of the most-affected muscle. Tremor frequency, when tremor was present, did not change throughout the
task. The intensity of tremor significantly increased during the task in all subjects.
fPEAK = peak frequency; fAVG = average frequency; PPEAK = tremor power peak; PAVG = tremor power average; “–“ refers to absence of tremor activity at EMG.
Note that given the randomized presentation of the visual and auditory stimuli, the EoT time differed among subjects (ranging from 127 to 198 s).
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FIGURE 1 | Tremor behavior during the audio-visual (A-V200) task in
one patient. Upper box: Audio-visual task (A-V200 task). Red lines indicate
when flashed white disk and noise were not simultaneous, blue lines when
they were simultaneous. The stimulus onset asynchrony between the
visual and the auditory stimuli was set at 200ms (visual preceding
auditory). A total of 50 visual and auditory stimuli were presented. Space
between lines indicate time interval (ranging between 2.5 and 7 s). Mid
box: EMG recordings (in blue), high-pass filtered off-line at 60Hz and
rectified. Single vertical lines (in black) show the start and end of the A-V200
task, respectively. Lower box: Spectral analysis of tremor activity showing a
sustained tremor frequency at 4.2 Hz. The harmonic double tremor
frequency is also clearly represented. The power of EMG signals (intensity
of tremor) is shown in colors (right column scale).
The LC is a cluster of NA-containing neurons located in the
upper dorsolateral pontine tegmentum. LC neurons fire in a tonic
or phasic mode (Aston-Jones and Cohen, 2005). Tonic activity is
characterized by sustained and highly regular discharge pattern
that is highest during wakefulness, decreases during slow-wave
sleep, and virtually ceases during Rapid Eye Movement (REM)
sleep. LC phasic mode involves activation of LC neurons follow-
ing task-relevant processes in response to environmental stimuli
that elicit behavioral arousal and exploratory behavior (Aston-
Jones and Cohen, 2005). Animal studies reported that neurons
in the LC can show also a synchronous activity. Synchronous
oscillations would rely on electronic coupling and are seem-
ingly independent of synaptic transmission. Electrotonic cou-
pling between LC neurons could serve to facilitate synchrony
in the event of a large afferent input (Ishimatsu and Williams,
1996).
LC neurons have extensively branched axons that project
throughout the neuraxis and provide the sole source of NA
to the neocortex, cerebellum, and most of the thalamus (Aston-
Jones and Cohen, 2005), all possibly involved in tremor onset. In
particular, the release of NA from LC axons causes inhibition of
ongoing purkinje cell activity, thus facilitating one or more func-
tions of regions under purkinje inhibitory control. Noradrenergic
input to the thalamic cells promotes a single spike-firing mode
of activity in the thalamus that has been related to increased
cortical activity and responsiveness. The LC also innervates
extensively and it is the sole source of cortical NA. It is likely
that this noradrenergic input to the neocortex is excitatory
and contributes to the generally recognized role of the LC as
a major wakefulness-promoting nucleus (Samuels and Szabadi,
2008a,b).
The biochemistry of NA neurons has great relevance to PD
(Delaville et al., 2011; Isaias et al., 2011). Of note, in the
normal condition, dopamine β-hydroxylase synthesizes NA from
dopamine. The LC-NA system modulates the survival of its tar-
get neuronal populations, which include dopaminergic neurons
in the substantia nigra (Mavridis et al., 1991; Frey et al., 1997;
Rommelfanger andWeinshenker, 2007). The LCmay also directly
influence the activity of the nigrostriatal dopaminergic system.
Single-cell recording studies demonstrated a noradrenergic mod-
ulation of midbrain dopamine neuronal activity consistent with a
direct pathway from the LC to the substantia nigra. In particular,
injections of the adrenergic neurotoxin N-(2-Chloroethyl)-N-
ethyl-2 bromo benzylamine hydrochloride (DSP-4) in the ventral
tegmental area or direct lesioning of the LC by local injec-
tion of 6-hydroxy-dopamine (6-OHDA) resulted in a significant
decrease in the basal release of dopamine in the caudate nucleus
(Collingridge et al., 1979; Lategan et al., 1992), and result in the
compensatory up-regulation of striatal D2 receptors (Harro et al.,
2003). NA facilitates burst firing of substantia nigra pars com-
pacta, while administration of the α1-adrenoceptor antagonist
prazosin attenuates firing (Grenhoff and Swensson, 1993).
The LC is thought to degenerate in PD as part of the dis-
ease pathology (Braak et al., 2003). Still, Lewy pathology poorly
correlates with neuronal loss in specific areas, thus its predic-
tive validity for neuronal disintegration is questionable (Jellinger,
2009). Moreover, noradrenergic neurons in the LC are relatively
preserved in early PD (Isaias et al., 2011; Pavese et al., 2011) and
do not exhibit the same intracellular changes as in the substan-
tia nigra (Halliday et al., 2005). Finally, the LC may degenerate
only in specific PD patients (Cash et al., 1987). Of interest, animal
studies showed a significantly increased activity of noradrenergic
neurons in LC after unilateral lesion of the nigrostriatal pathway
(Wang et al., 2009).
Mevawalla and colleagues (Mevawalla et al., 2009) reported a
case of unilateral rest tremor in a patient with vascular parkin-
sonism and contralateral lesion of the LC. The Authors suggest
that the unilateral LC lesion contributed to the pathogenesis
of contralateral tremor. There are several concerns related to
this clinical case that prevent any firm conclusion. The patient
suffered from vascular parkinsonism and macroscopically pre-
sented vascular lesions in the globus pallidus bilaterally, right
putamen and internal capsule. The presence of tongue tremor
supports a cerebellar involvement, which was not investigated
by the Authors. Moreover, no functional studies have been car-
ried out in vivo, nor functional staining (e.g., TH-staining) in
ex vivo specimina. Last but not least, the LC projects almost
exclusively ipsilaterally and, therefore, the tremor would relate to
the intact LC rather than the lesioned one. This would eventu-
ally support, rather than confute our hypothesis. Still, based on
our preliminary results, we cannot exclude that tremor in PD
derives from a paradoxical effect of NA and dopamine depletion
(Dzirasa et al., 2010).
The main limitation of this study relates to poor specificity
of the A-V200 task. Still, this task proved to selectively activate
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the brainstem in an in vivo imaging study (Raizada and Poldrack,
2008). We also did not find changes in tremor activity during
A-V100 and A-Vnull trials, both tasks being not able to elicit an
activation of brainstem but of other brain areas (i.e., frontal
region) (Raizada and Poldrack, 2008).
Secondly, the LC-NA system and the noradrenaline molec-
ular transporters (NET) should be ideally investigated in vivo
by dedicated, highly specific radiotracers displaying low back-
ground non-NET binding, high sensitivity to variations in NET
density, and fast kinetics. As such, a radiotracer is not avail-
able for large clinical studies, we retrospectively collected data
of SPECT with FP-CIT in a large, homogeneous cohort of
PD patients out of our database (Centro per la Malattia di
Parkinson e i Disturbi del Movimento, Milano). Although FP-
CIT is mainly used for assessing striatal dopamine reuptake
transporters (DATs), it has shown some, albeit lower, sensitiv-
ity, to NET (Booij and Kemp, 2008). Hence, when applied to
an anatomical region with known low DAT capacity such as the
LC, it allows investigation on the NA-dependent synaptic activ-
ity (Isaias et al., 2011). In the brainstem, no other anatomical
region, beside the LC, show clearly detectable density of NET
(nor DAT).
Studying the LC can be challenging to say the least. In partic-
ular, (1) directly recording in humans the activity of LC is not
applicable given its anatomical structure and location; (2) the size
of LC is at the spatial resolution limits of currently available imag-
ing techniques; and (3) even receptor binding (or displacement)
studies and PET might not catch its phasic electrical activity.
Anyhow, along our results, it is tempting to hypothesize an active
role of the LC-NA system in triggering tremor onset in PD. While
the frequency of parkinsonian tremor might be related to the
intrinsic oscillating properties of dopamine depleted circuits, the
onset and intensity of tremor might relate to the activity of the LC
and of its noradrenergic output.
The introduction of the LC in the neural network dynamics
of parkinsonian tremor might well explain many of its remark-
able features. In particular, (1) tremor would appear only in PD
subject with no functional damages of the LC; (2) eventually,
along with PD progression and a consequent degeneration of LC-
NA system, tremor will diminish; (3) tremor will appear during
maneuvers that trigger LC activity, above all stress; and (4) PD
patients do not manifest tremor during sleep being the LC silent.
Finally, given a putative neuroprotective and compensatory activ-
ity of LC-NA on its target cells (including the substantia nigra and
the striatum), it is tempting to speculate that an intact, or hyper-
active, LC-NA system might be responsible for a more benign
progression of PD in patients with tremor.
In conclusion, parkinsonian tremor would be the outcome of
subtle derangements in the finely tuned NA-DA interplay, where
the dopaminergic failure would involve complex noradrenergic
adjustments leading to motor anomalies in the presence of an
intact LC, which might be only a necessary state but not the direct
cause of rest tremor in PD.
All these pending questions obviously require further stud-
ies in the future both by imaging and laboratory techniques. On
this track, we hypothesize that parkinsonian tremor might rep-
resent the clinical sign of an enhanced LC activity as possible
compensatory process over dopaminergic loss.
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The game's afoot; Follow your spirit: and upon this 
charge, Cry — God for Harry! England and Saint George!  
[W. Shakespeare, Henry V (scene i)] 
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Evidence of a role of LC-NAergic system in Parkinson tremor:  
a reserpine rat model study 
 
In this study we were interested in describing reserpine-induced tremor in rats pre-treated with 
DSP-4, a selective LC-NAergic neurotoxin. This is a rather simple and straightforward study but 
has the great value to possibly disentangle the LC-NAergic effect on tremor onset from a 
concomitant role of other amines (e.g. DA and serotonin). Moreover, this study could provide 
direct evidence of the involvement of the LC in the onset of Parkinson tremor. Indeed, if the 
NAergic system does play a role in Parkinson tremor onset, a selective damaging of LC, by means 
of DSP-4, would prevent its appearance after reserpine injections.  
We recorded tremor in 12 male Sprague Dawley rats (200-220g) treated with reserpine (10 mg/Kg 
i.p.) and in 12 rats (matched for gender, age and weight) treated two weeks ahead with DSP-4 (50 
mg/Kg i.p.) before receiving reserpine (also 10 mg/Kg i.p.). The presence, frequency and 
amplitude of tremor was documented by means of an accelerometer placed on the lower left limbs 
of the rat for 2 consecutive minutes before and at 20, 40, 60, 80, 100, 120, 180 minutes after reserpine 
injection.  
The reserpinized rat has been more widely recognized as an animal model for PD. Reserpine binds 
to vesicular monoamine transporter (VMAT) with high affinity (Ki at subnanomolar concentration) 
(Henry et al., 1998), blocking neurotransmitter uptake into the vesicle and ultimately depleting 
catecholamines from storage vesicles (Henry et al., 1987; Kirshner, 1962a; Kirshner, 1962b). The 
actions of reserpine on the VMAT result in an acute catecholamine release, followed by chronic 
inhibition of catecholamine secretion, as a result of diminished releasable stores of vesicular 
catecholamine (Carmichael et al., 1980; Slotkin and Edwards, 1973). Reserpine induces symptoms 
resembling those of PD in humans (Flach, 1955; Kline and Stanley, 1955) and laboratory animals 
(Glow, 1959; Windle and Cammermayer, 1958). In the rat, reserpine induces rigidity of skeletal 
muscles, postural flexion, hypokinesia and tremor (Colpaert, 1987). Among rodent models of 
tremor, the reserpinized rat possibly represent the only model of (Parkinson) tremor with a clear 
(and maybe solely) involvement of the BG, or at least of catecholamine pathways (Miwa, 2007). No 
other rodent model of PD (e.g. 6-OHDA or MPTP induced) shows tremor. On the contrary to 
rigidity, tremor is present also at a low dose of reserpine (2.5 mg/Kg) and does not enhance in 
frequency or amplitude at higher doses. Tremor reaches its maximal amplitude within 40 min after 
reserpine injections, while other symptoms (i.e. bradykinesia and rigidity) reached a peak at 60-100 
min after injection (see also Figure 1 in Colpaert, 1987). The main issue of reserpine-induced motor 
disturbances is the great variability within and between each rat (Goldstein et al., 1975), thus 
making it difficult to define and quantify possible effects of drugs on symptoms. Anyhow, in our 
study we were more interested in the presence/absence of tremor. Besides blind scoring of video 
recordings, tremor was described by means of an accelerometer thus allowing an objective 
measurement of tremor appearance, frequency and amplitude (see Figure below). Our study 
follows preliminary evidence of tremor amelioration in rats with tremorine-induced tremor by 
means of a unilateral electrolesion of LC (Dickinson and Slater, 1982). It is worth mentioning that 
the primary mechanism responsible for tremorine-induced motor phenomena almost certainly 
involves central cholinergic neurons rather than aminergic ones.  
DSP-4 can be used for the temporary selective degradation of the central and peripheral NAergic 
neurons, mainly those from the LC (for review Hormigo et al., 2012). It has been suggested that this 
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selectivity of DSP-4 toward LC neurons may be related to the significant difference found in the 
affinity of DSP-4 for the NA uptake carrier in different brain structures (Zaczek et al., 1990). In 
rodents, a systemic injection of DSP-4 causes depletion in the levels of NA, in the release capacity 
and in the activity of DBH (Ross et al., 1973 and 1985). The effects of DSP-4 administration on the 
behavior of rats (open-field tests) can include neophobia (distorted reactions to new things or 
experiences), increased emotionality (more grooming activities and number of stools), defensive or 
submissive behavior, an altered resident/intruder paradigm, increased aggressiveness and a lack 
of fear to environmental factors (Spyraki et al., 1982; Delini-Stula et al., 1984; Cornwell-Jones et al., 
1992; Harro et al., 1995; van den Buuse et al., 2001). More recent studies in non-human primates 
and genetic mice models of PD also described severe motor deficits similar to those reported after 
6-OHDA lesion (Pifl et al., 1991; Rommelfanger and Weinshenker, 2007, Delaville et al., 2011). Of 
relevance, in contrast to a 6-OHDA lesion (Deumens et al., 2002), the motor impairments 
consequent to NA depletion were not related to DAergic cell loss and the motor deficits described 
in 6-OHDA-lesioned rats is aggravated by the additional depletion of NA (Delaville et al., 2011). 
Another study has reported that denervation of LC NAergic terminals potentiated the 6-OHDA-
induced partial DAergic neurodegeneration and akinesia only in rats treated with a D2 receptor 
antagonist, haloperidol (Srinivasan and Schmidt, 2003). 
So far, we were able to validate the reserpinized rat as a model for Parkinson tremor (see Figure 
below). Pending activity are still the behavior and tremor evaluation of DSP-4 pre-treated rats after 
reserpine injection and the tyrosine hydroxylase (TH)-staining to document LC lesioning by DSP-4. 
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Tremor behavior in one rat induced by 10 mg/Kg reserpine at 40 minutes after injection. Upper 
box: continuous recordings (first 45 sec.). Lower box: close up at about 20 sec. showing tremor 
presence. Tremor was recorded at lower left limb while the rat was laying on the right side 
(lower left limb was elevated). The power of EMG signals (intensity of tremor) is shown in 
colors (right column scale).  
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Correlations between iron content in the LC and SN with 
dopaminergic striatal innervation in subjects with PD 
 
Aim of this study was to measure by means of 3 Tesla Magnetic resonance imaging (MRI) iron 
content in the LC, as a putative indirect measurement of cell damage, and to correlate it with 
striatal DAergic innervation loss, measured by SPECT and FP-CIT. We expect PD patients with 
predominant tremor to show less iron content in the LC in comparison to PD patients with mainly 
akinetic-rigid signs, regardless of DAergic striatal innervation loss. We also predict that iron 
deposition in the LC would negatively correlate with iron deposit in the SN and possibly also with 
striatal DAT binding loss. Such findings would further support the hypothesis of a neuroprotective 
and compensatory role of LC-NAergic system on DAergic one (see Background and Hypothesis 
statement).  
Of relevance, despite its great potential value, this study should be considered a preliminary 
anatomical study aiming to improve targeting of LC for future activation studies (by means of 
functional MRI). Indeed, in the future, we aim to investigate PD patients with tremor by means of 
EMG recording, brain imaging (e.g. functional MRI) and possibly coherence analysis (i.e. EEG).  
The presence of iron deposition in the BG appears to play a pivotal role in the manifestation of 
parkinsonian-like features or Parkinsonism caused by DA deficiency. Increased iron levels in PD 
have been demonstrated using both quantitative (biochemical analysis using postmortem brain 
tissue) and semi-quantitative methods (i.e. histochemical methods, transcranial sonography, MRI 
imaging techniques) (Dexter et al. 1991; Sian-Hülsmann J et al., 2011). In brief, the sources of 
augmented iron in subjects with PD could be related to (1) a dysregulation of iron homeostasis 
caused by pathological variation in iron tissue distribution or (2) a malfunction in molecules 
involved in sequestrating excess iron, above all ferritin and NM (Bazelom et al., 1967; Sian-
Hülsmann J et al., 2011). Regardless whether iron accumulation represents the cause or the result of 
neuronal destruction, an increase in iron content may exacerbate the neuronal damage and 
indirectly contribute to the average duration of the disease. Accordingly, MRI studies described a 
positive correlation between degree of nigral iron elevation and severity of the motor symptoms 
(Bartzokis et al. 1999). Still, no nigral iron changes (Dexter et al. 1992) have been found in the SN of 
pre-symptomatic PD or incidental Lewy body disease (although this has been disputed) and mild 
PD (Riederer et al. 1989) and excessive iron deposits in the SN do not correlate with disease 
duration (Wallis et al. 2008). Iron deposits in the LC have not been consistently studied in subjects 
with PD.  
The contrast underlying structural MRI results from T1 and T2 relaxation times, which characterize 
how fast water magnetization returns to equilibrium after perturbation by a radiofrequency (RF) 
pulse. During an MR sequence, an RF pulse results in changes to longitudinal (T1) and transversal 
(T2) components of the MR signal, after which the T1 and T2 components return to equilibrium via 
exponential increase (for T1 relaxation) or decrease (for T2 relaxation). T1 and T2 relaxation times 
correspond to the time constant of this exponential function, that is, a return to two thirds of 
baseline value (in milliseconds). R1 and R2 relaxation rates correspond to 1/T1 and 1/T2, 
respectively. T1 and T2 relaxation times are a characteristic of tissue composition and therefore 
vary depending on its molecular structure. T2 is particularly sensitive to local magnetic field 
inhomogeneities and therefore is modified in the presence of metallic particles such as iron. The 
apparent transverse relaxation time, T2* (T2 star), takes into account the contribution of magnetic 
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field inhomogeneities. The corresponding relaxation rate is denoted by R2* 1⁄4 1/T2*. A gradient-
echo image is T2*-weighted, whereas a spin-echo image is T2-weighted. Structures that accumulate 
iron appear hypointense on T2-weighted and T2*-weighted MR images, and many experiments 
have shown that the relaxation rate is a noninvasive estimate of iron content (from Hardy et al., 
2005 and Lehéricy et al., 2012). These results are promising to improve the targeting of the LC in 
structural scans, but attempts to ascribe functional MRI activity to the LC still face the problem of 
determining whether activation observed in the lower resolution BOLD images truly corresponds 
to the LC tissue identified in a higher resolution anatomical scan. NM has paramagnetic T1-
shortening effects when combined with metals such as iron and copper (Enochs et al., 1997; Zecca 
et al., 2003). This means that on T1-weighted images with high spatial resolution at 3 Tesla, LC and 
SN (in particular SNc) appear as areas of high signal intensity. Indeed, recent anatomical MRI 
studies have used NM as an in vivo marker of the LC in humans (Sasaki et al., 2006).  
We first aimed to validate what described by Sasaki and coll. (Sasaki et al., 2006) and confirmed a 
slight hyperintensity of LC (Image 1), and possibly SN (Image 2), on T1 weighted images. We then 
tried to quantify the T1 values in these areas for possible correlations. On the contrary to Sasaki 
and coll. (Sasaki et al., 2006) we found little distinction of both the LC and SN in these maps 
suggesting it is not characterized by difference T1 values (Image 3 and 4). Given these doubtful 
results when looking at NM via T1 imaging, we preferred investigating iron deposition via another 
MRI modality. Preliminary results (Image 5 and 6) were encouraging. 
We are currently studying best MRI sequences to measure iron content in the LC area and SN. At 
the moment, preliminary data were obtained in five PD patients (two with tremor) and four 
healthy controls.  
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Image 1 
 
 
 
 
 
 
 
 
 
 
 
Dr. Isaias Ioannis Ugo – matr. R08854 – Università degli Studi di Milano, Dipartimento di Fisiopatologia e dei Trapianti – Academic 
year: 2012 – PhD thesis in Human Physiology: “A role for locus coeruleus in Parkinson tremor”. 
 !
31 
 
Image 2 
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Image 3 (and 4). T1map – Quantitative estimates of T1 based on gradient echo images (not 
shown). 
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Image 4  
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Image 5 – T2* weighted image showing strong hypointensity in the brainstem nuclei. 
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Image 6 – Signal phase image from T2* scan, showing hyperintensity due to susceptibility effect 
of iron in the nuclei. A more sophisticated data processing is required in order to eliminate the 
background magnetic field uniformities that give rise to the dark-light bands near the perimeter 
of the brain. These scans could be used to provide a semi-quantitative assessment of myelin 
density in white matter and iron (or generically metal) content in grey matter. 
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SUMMARY AND FUTURE DIRECTIONS 
 
In summary, we first suggested that in PD patients at an early stage the LC-NAergic system might 
be intact and even hyperfunctioning (Isaias et al., 2011). We then described preliminary evidence of 
a link between LC-NAergic activity and Parkinson tremor (Isaias et al., 2012). We now aim to 
confirm, in the reserpinized rat model for PD, a distinct role of LC-NAergic system in Parkinson 
tremor and to disentangle it from the influence of other amines (e.g. serotonin, Caretti et al., 2008). 
A second on-going study will serve to enhance accuracy in targeting LC and to obtain preliminary 
in vivo evidence of a putative neuroprotective role of LC-NAergic system in PD patients with 
tremor. This study will also provide preliminary data for future activation studies (e.g. by means of 
functional MRI) possibly describing in vivo the LC activity (Raizada and Poldrack, 2008).  
 
Understanding the physiological interactions between NA and DA pathology in PD is of great 
relevance as it could lead to novel therapies with the potential to compensate for, and protect from, 
DAergic neurons loss. Still, many issues need to be addressed in order to move forward with 
testing NAergic drugs as potential PD treatments.  
It appears that the LC may somehow compensate for DA loss (see Introduction), but how and where 
it does so remains unclear, as NAergic innervation of the nigrostriatal system is sparse (Mavridis et 
al., 1991; Bing et al., 1994; Fornai et al., 1997). Stated that the LC facilitates SN activity (Grenhoff et 
al., 1988 and 1993) (see Background), it is tempting to speculate that the NAergic system may 
compensate DAergic activity by a direct up-regulation. PET imaging studies, targeting in vivo the 
NAergic terminals, will provide important data to support this hypothesis. The LC might also 
protect DAergic neurons by a NA-related trophic activity. As mentioned above (see Background), 
one consistent finding is that NA suppresses the expression of proinflammatory molecules and 
elevates the expression of anti-inflammatory molecules (Feinstein et al., 2002). Furthermore, NA 
and DA have equal antioxidant potential and can reduce oxidative stress and protect 
mesencephalic cultures from death (Troadec et al., 2001). Healy and coll. have also shown that a 
polymorphism resulting in low DBH activity in human patients correlates with a lower incidence 
of PD (Healy et al., 2004). A direct role for DBH in mitochondrial function and the modulation of 
free radical production deserves further investigation.  
A second relevant question regarding neuroprotection mediated by the LC is timing. At what point 
in the degenerative process is the NAergic system recruited to protect or compensate for dying 
DAergic neurons? For example, would a NAergic supplements act as a prophylactic treatment for 
PD, or would NAergic drugs be helpful even after the neurons have begun to die and the disease 
has manifested into clinical signs? Would treatments need to be chronic or would more acute 
regimens suffice? More detailed experiments testing different administration paradigms of NA 
pharmacotherapies in PD animal models could begin to answer these questions. 
Above all future lines of research, the effect of LC activity on DAergic drugs should be also 
investigated. The side effects associated with long-term levodopa treatment, such as abnormal 
involuntary movements (i.e. dyskinesia), represent an important cause of functional disability and 
remain difficult to manage. The causes of levodopa-induced dyskinesia are unclear. It probably 
involves non-physiological pulsatile stimulation of DAergic receptors or non-physiological release 
of DA (e.g. from serotonergic nerve terminals) in the striatum (Tanaka et al., 1999; Carta et al., 2007; 
Navailles et al., 2010b). Recently, a dysfunctioning LC has been correlated with the onset of 
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levodopa-induced dyskinesia (Fornai et al., 2007). Of relevance, NAergic neurons do not release 
DA synthesized from levodopa (Navailles et al., 2010a,b) but could participate in the clearance of 
extracellular DA. Because NET is able to transport DA, NAergic fibers could modify the pattern of 
levodopa-induced DA release depending on the relative innervation of brain regions by NAergic 
neurons. Indeed, in MPTP-treated monkeys, idazoxan (α2 ARs antagonist) in combination with 
levodopa did not impair the anti-parkinsonian response but significantly reduced dyskinesia and 
delayed their onset (Henry et al., 1999; Grondin et al., 2000; Fox et al., 2001). The same 
antidyskinetic effect was confirmed by other α2 ARs antagonists (i.e. fipamezole, yohimbine and 
rauwolscine) (Gomez-Mancilla and Bedard, 1993; Henry et al., 1999; Grondin et al., 2000; Savola et 
al., 2003; Fox and Brotchie, 2010). In humans, however, neither idazoxan nor fipamezole had any 
effect on duration of drugs-on time (Rascol et al., 1994). It is not clear whether the doses and routes 
employed of either drug might have impaired their efficacy. Indeed, the appearance of side-effects 
(i.e. hypertension, facial flushing and headache) prevented using high, and possibly more 
efficacious, doses (Fox and Brotchie, 2010). The efficacy of these drugs would be also critically 
dependent on the status of LC-NAergic fibers (from Logan et al., 2007 and Delaville et al., 2011). 
There are good theoretical and clinical reasons, and encouraging preliminary results, to consider 
NAergic compounds for the treatment of different PD symptoms, possibly including tremor. The 
development of a direct investigation in patients of LC functionality and innervation, by means of 
functional MRI and PET, is now mandatory.   
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Abstract
To determine the role of striatal dopaminergic innervation on upper limb synergies during walking, we measured arm
kinematics in 13 subjects with Parkinson disease. Patients were recruited according to several inclusion criteria to represent
the best possible in vivo model of dopaminergic denervation. Of relevance, we included only subjects with normal spatio-
temporal parameters of the stride and gait speed to avoid an impairment of upper limbs locomotor synergies as a
consequence of gait impairment per se. Dopaminergic innervation of the striatum was measured by FP-CIT and SPECT. All
patients showed a reduction of gait-associated arms movement. No linear correlation was found between arm ROM
reduction and contralateral dopaminergic putaminal innervation loss. Still, a partition analysis revealed a 80% chance of
reduced arm ROM when putaminal dopamine content loss was .47%. A significant correlation was described between the
asymmetry indices of the swinging of the two arms and dopaminergic striatal innervation. When arm ROM was reduced, we
found a positive correlation between upper-lower limb phase shift modulation (at different gait velocities) and striatal
dopaminergic innervation. These findings are preliminary evidence that dopaminergic striatal tone plays a modulatory role
in upper-limb locomotor synergies and upper-lower limb coupling while walking at different velocities.
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Introduction
Upper limb locomotor synergies are a basic component of
human gait. They represent an active phenomenon driven by
locomotor centers within spinal cord and the brainstem and
modulated by cortical and subcortical inputs [1,2]. Information on
neural control of locomotor automatism and gait-related arm
motion in humans is still scanty. Animal studies, as well as
preliminary functional imaging studies in humans, indicate that
locomotor movements are coordinated by spinal networks referred
to as a central pattern generators (CPGs), which are governed by
the brainstem locomotor command region that, in turn, is under
the control of the basal ganglia and premotor cortex [3–9].
Parkinson disease (PD) is a progressive neurological condition
characterized by bradykinesia, rigidity, postural instability and
possibly tremor. Patients with PD typically show little or no arm
oscillation while walking, and this is often the first clinical motor
sign to appear [10,11]. In PD patients, the arm swing is not
correlated with clinically tested shoulder rigidity [10] and often
disproportional to the degree of upper limb akinesia during
voluntary alternating movements, thus pointing to a task-specific
motor disturbance associated with walking. At an anatomopatho-
logical level, PD is mainly characterized by the loss of
dopaminergic neurons in the substantia nigra pars compacta,
which leads to striatal dopamine depletion [12]. It has been
estimated that motor PD symptoms appear when the loss of
dopamine neurons reaches the 50% to 60% threshold, [13] which
corresponds to a 70% to 80% decrease in putaminal dopamine
content [14].
The aim of this study is to investigate a putative role of
dopamine and the striatum in locomotor upper limb automatism,
taking into account their relationship with walking speed. Patients
were carefully selected to represent a clinically homogenous in vivo
model of dopaminergic striatal innervation loss (see, Subjects) which
was measured by [123I] N-v-fluoropropyl-2b-carbomethoxy-3b-
(4-iodophenyl) tropane (FP-CIT) and single-photon computed
tomography (SPECT).
Materials and Methods
Ethics Statement
The local institutional review board (Section of Human
Physiology, DePT) approved the study and all patients provided
written informed consent.
Subjects
We tested 13 subjects with idiopathic PD (six males; mean age:
64 years; range: 52–73 years; disease duration mean: 5 years;
range: 3–6) and a control group (HC) of 10 neurologically healthy
adults (seven males; mean age: 64 years; age range: 55–70 years).
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The diagnosis of PD was made according to the UK Parkinson
Disease Brain Bank criteria and patients were clinically evaluated
by means of the Unified Parkinson Disease Rating Scale motor
part (UPDRS-III; range: 0–108). Median UPDRS-III score was 21
(range: 11–32). A sub-score for unilateral arm rigidity and
bradykinesia (UPDRSrb) was calculated as the sum of UPDRS
items 22 (rigidity), 23 (finger taps), 24 (hand movements), 25 (rapid
alternating movements of hands). Median UPDRSrb score of the
worst arm was 8 (range: 4–11) and of the less affected arm was 4
(range: 1–5). We selected only mildly affected patients for this
study (Hoehn & Yahr II) (see later).
At the time of the study, and during a follow-up time of at least
six months after enrollment, no patient showed any signs
indicative for atypical parkinsonism (e.g. gaze abnormalities,
autonomic dysfunction, psychiatric disturbances, etc.). All patients
reported a marked improvement (.30% UPDRS-III score
reduction) after the intake of L-Dopa or dopamine agonists. L-
Dopa daily dose and L-Dopa Equivalent Daily Doses (LEDDs)
were also recorded, with the latter calculated according to the
following conversion ratio: 100 mg levodopa= 1.5 mg pramipex-
ole = 6 mg ropinirole. Median value of LEDDs per day was
500 mg (range 200–625 mg).
All subjects were screened for cognitive impairment by the
Mini-Mental State examination, Clock Drawing Test and Frontal
Assessment Battery and excluded if not meeting normal, age-
related performance.
Other exclusion criteria for study participation were a history of
neurological disorders (other than PD for patients), head trauma
with loss of consciousness, orthopedic diseases, systemic illness or
previous orthopedic, brain or spinal cord surgery. A MRI was
performed within six months from enrollment and only subjects
with normal results (i.e., no sign of white matter lesion or atrophy)
participated in the study.
Gait disturbance is a key component of motor disability of PD
and patients may variably present with reduced gait speed,
shortened stride length, prolonged stance and double support
phases [15]. At an early disease stage, PD patients may still show
normal spatio-temporal gait parameters during steady linear
walking [16]. To avoid an impairment of upper limbs locomotor
synergies as a consequence of gait impairment per se, we enrolled
only PD patients with normal spatio-temporal parameters of the
stride (Table 1).
Experimental Protocol and Data Processing
After a 3-day washout of antiparkinsonian medication, subjects
performed three sets of six walking trials, at a self-chosen
‘‘preferred’’ speed, ‘‘slow’’ and ‘‘fast’’ speed, in random order
along a 10 m path, following verbal instruction in the absence of
external feedback. Set-up and data processing has been extensively
described elsewhere [16,17]. In brief, kinematics of body segments
were measured during walking, using an optoelectronic system
(SMART, BTS, Milan, Italy, sampling frequency 60 frames/s),
which computed the 3D coordinates of spherical markers (15 mm
diameter) attached on bony fixed landmarks. The marker
coordinates were low-pass filtered (cut-off frequency 3–7 Hz,
self-estimated by a linear-phase autoregressive model-based
derivative assessment algorithm). Specific sets of parameters for
the characterization of each task were automatically extracted by
ad hoc algorithms and then visually inspected to check for possible
errors. In particular, the time course of the angular displacement
of the humerus segment of the arm with respect to the vertical
(positive forward) [17] were computed in planes perpendicular to
the inter-acromion line. These measures allowed to analyze the
pendular behavior of the arm segment independently from
shoulder and pelvic girdle horizontal rotation associated with
trunk torsion. Angular profiles were normalized in time as a
percentage of the stride duration, and for each cycle we extracted
the range of motion (ROM) of absolute arm angle. Finally, arm
swing asymmetry (ASA) was calculated according to Zifchock and
coll. [18] as follows: ASA= (45u-arctan(ArmSwingLEFT/ArmS-
wingRIGHT))*100/90u.
For arm ROM larger than 3u, the phase-shift (upper-lower limb)
was further computed as the temporal delay between the positive
peak (antero-posterior swing) of the wrist and the negative peak of
malleolus, between 20% and 80% of the stride cycle. When the
upper limb produced two oscillations per stride, which may occur
at the lower walking speeds, phase-shifts were computed using the
first positive peak of arm oscillation.
For each subject all variables (e.g. gait speed, arm ROM, phase-
shift, etc.) were averaged over trials.
To characterize the speed-related effects, the slopes of the
regression lines of arm ROM, phase-shift as well as of spatio-
temporal parameters of the stride were computed for each subject
as a function of the gait speed.
SPECT Data Acquisition, Processing and Analysis
Dopamine-transporter (DAT) values were measured by means
of Single Photon Computed Tomography (SPECT) with [123I] N-
v-fluoropropyl-2b-carbomethoxy-3b-(4-iodophenyl) tropane (FP-
CIT).
SPECT data acquisition and reconstruction has been described
in details elsewhere [19]. In brief, intravenous administration of
110–140 MBq of FP-CIT (DaTSCAN, GE-Healthcare, UK) was
performed 30–40 minutes after thyroid blockade (10–15 mg of
Lugol oral solution) in PD patients subsequently overnight
withdrawal of dopaminergic therapy. Data were compared with
a group of 15 healthy subjects (four males; mean age, 62; age
range: 44–70 years).
Brain SPECT was performed by means of a dedicated triple
detector gamma-camera (Prism 3000, Philips, Eindhoven, the
Netherlands) equipped with low-energy ultra-high resolution fan
beam collimators (4 subsets of acquisitions, matrix size 1286128,
radius of rotation 12.9–13.9 cm, continuous rotation, angular
sampling: 3 degree, duration: 28 minutes).
Brain sections were reconstructed with an iterative algorithm
(OSEM, 4 iterations and 15 subsets) and then processed by 3D
filtering (Butterworth, order 5, cut-off 0.31 pixel-1) and attenua-
tion correction (Chang method, factor 0.12).
FP-CIT uptake values for the caudate nucleus and putamen of
both PD patients and healthy subjects were calculated according
to Basal Ganglia Matching Tool [20].
Striatal uptake values were used to calculate an asymmetry
index (AI), as follows: AI = (VOILEFT – VOIRIGHT)/(VOILEFT+-
VOIRIGHT)*200.
General Statistical Analysis
Distribution was non-normal for most of the variables, as
assessed by Shapiro-Wilk’s test. Accordingly, descriptive statistics
and comparisons were always based on median/range values and
non-parametric tests, respectively.
ChiSquare was used to test demographic homogeneity among
groups regarding gender.
To relate comparisons to DAT binding values, upper and lower
limbs were also re-classified into ipsilateral and contralateral
according to the putamen with greater dopaminergic innervation
loss. For healthy controls, left hemibody refers conventionally to
ipsilateral.
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Differences in spatio-temporal gait parameters, arm ROM,
phase shifts indexes and slope parameters between control and
patient groups were analyzed by means of Wilcoxon two-sample
test.
To quantify the (in)consistency of these measures and the stride-
to-stride variability, we calculated the coefficient of variation (CV)
of these measures when walking at preferred gait speed.
When comparing two hemibodies of the same subject (both for
kinematic as well as DAT binding values) we applied a Wilcoxon
matched pair test.
Hoeffding’s D measure was used to identify correlations among
DAT binding values and biomechanic data (including asymmetry
indexes) that differed among patients and healthy controls. If no
linear correlation was found, we applied partition analyses in
search for a DAT binding cut-off value related to abnormal
kinematic parameters.
Statistical analyses were performed with the JMP statistical
package, version 8.0.2 (SAS Institute, Inc., Cary, NC, USA).
Results
No difference was found among PD patients and HC for gender
distribution and age.
Imaging Findings
In comparison to HC, patients showed reduced DAT binding
values in the putamen (PD, right median: 2.19; right range: 1.2–
3.51; left median: 2.63, left range: 1.41–3.4; HC, right median:
4.94, right range: 3.07–5.71; left median: 4.94, left range: 2.96–
5.71; p,0.01 all) and caudate nucleus (PD, right median: 4.06;
right range: 2.74–5.49; left median: 4.17, left range: 2.3–4.94; HC,
right median 5.16, right range: 3.18–6.48; left median: 5.05, left
range: 3.07–6.7; p,0.05 all) thus further supporting the clinical
diagnosis of PD. In HC, no difference was described when
comparing DAT binding values of right and left hemisphere. In
PD patients, DAT binding values of the most affected putamen
(median: 1.97; range: 1.2–3.07) were on average 30% lower than
in the opposite hemisphere (median: 2.85; range: 1.86–3.51;
p,0.01). No statistical difference was instead found when
comparing DAT binding values of the caudate nucleus of PD
patients (most affected, median: 3.73; range: 2.3–4.83; less
affected, median: 4.2; range: 2.74–5.5). Average AI value for the
putamen of PD patients was 30 (range 6–59); all HC had a
putamen AI score below 5 (putamen AI score average 2.1; range
0–4).
UPDRSrb score was negatively correlated with striatal DAT
binding values (p = 0.01, RSquare = 0.20), but this relationship
explained only 20% of the variance. This finding is in agreement
with previous results of SPECT and FP-CIT in subjects with PD
and confirms the validity of the methods applied in this study [21].
Walking at Preferred Speed
As expected, no difference was found for lower limbs spatio-
temporal gait parameters (i.e. stride length, stride time and stance)
between patients and controls at preferred gait speed (see, Subject).
In HC, right and left hemibodies did not show any difference for
any gait-related parameters (Table 1).
Consistency of the spatio-temporal measures did not differ
significantly between the patient and control group.
When arms were re-classified into ipsilateral and contralateral
to the more dopamine depleted hemisphere (see, General
statistical analysis), the contralateral arm ROM of PD patients
Table 1. Spatio-temporal parameters of the stride, arm ROM and phase shift of subjects with Parkinson disease and healthy
subjects.
Parkinson patients Healthy subjects
Gait speed (Km/h) 3.81 (1.86, 7.81) (preferred gait speed range: 2.87, 4.35) 3.82 (1.24, 9.94) (preferred gait speed range: 3.35, 4.4)
Contralateral Ipsilateral Contralateral (Right) Ipsilateral (Left)
Arm ROM (u) 7.48 (1.47, 32.06)** 18.19 (2.11, 29.8)** 25.27 (2.29, 31.8) 25.71 (5.21, 38,15)
Phase shift (%stride) 215.35 (223.1, 25.6)* 211.8 (216.9, 26.1) 210.17 (219.1, 25.4) 29.97 (218.9, 23.5)
Stride length (mm/BH) 0.68 (0.55, 0.28) 0.68 (0.49, 0.82) 0.7 (0.57, 0.82) 0.69 (0.54, 0.81)
Stride time (sec) 0.89 (0.73, 1.47) 0.92 (0.75, 1.42) 0.86 (0.8, 1,28) 0.87 (0.64, 1.28)
Stance (%stride) 65.2 (58.78, 71.25) 66.56 (62.77, 72.84) 64.42 (61.76, 72.6) 64.28 (61.54, 81.82)
Slope arm ROM
[u/(km h21)]
2.08 (0.12, 6.68) 3.47 (0.43, 7.82) 3.96 (2.1126.34) 3.5 (1.2426.58)
Slope phase shift
[%stride/(km h21)]
4.98 (2.9, 11.6)* 3.85 (2.52, 9.6)* 3.04 (1.5524.68) 2.88 (1.824.16)
Slope stride length
[mm/BH/(km h21)]
0.07 (0.05, 0.09) 0.08 (0.05, 0.09) 0.06 (0.0520.08) 0.07 (0.0520.08)
Slope stride time
[sec/(km h21)]
20.18 (20.3, 20.12) 20.17(20.3, 20.11) 20.16 (20.22, 20.09) 20.16 (20.23, 20.09)
Slope stance
[%stride/(km h21)]
20.18 (20.29, 20.12) 22.0 (23.7, 21.4) 20.15 (20.22, 20.1) 21.86 (22.55, 21.23)
Median values, non-outlier min-max, and levels of statistical difference (Mann-Whitney U-test or Matched pairs) are reported. Data refer at walking at different velocities
unless otherwise specified.
*p,0.05 (PD vs. HC); ** p,0.01 (PD vs. HC). BH= body height (mm). ROM= range of motion; Phase shift = temporal delay (%stride) between the positive peak (antero-
posterior swing) of the wrist and the negative peak of malleolus; Stride = the period from initial contact of one foot and following initial contact of the same foot, is one
gait cycle. Stance =gait phase when a foot is in contact with the ground, it begins with initial heel contact and ends with toe off.
For Parkinson patients, ipsilateral and contralateral refers to the more dopamine depleted hemisphere. For healthy controls, left hemibody refers conventionally to
ipsilateral.
doi:10.1371/journal.pone.0051464.t001
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was reduced when compared to the ipsilateral one (trend towards
significance, p= 0.07; Table 1). Contralateral arms also showed a
significant anticipation of maximum arm flexion (forward move-
ment) in relation to ipsilateral thigh extension (backward
movement), compared to controls (Table 1).
Of relevance, only four subjects with PD showed reduced arm
ROM bilaterally. The remaining nine patients had one arm with
ROM in the range of normality (ROM.18u [mean ROMHC-1SD
ROMHC]). In the latter group of patients, all but two arms with
reduced ROM were contralateral to the putamen with lower DAT
binding values. Still, the putamen corresponding to the arm with
ROM in the range of normality had over 45% DAT binding loss
(with respect to the median value of our normal subjects).
No linear correlation was found between arm ROM reduction
and dopaminergic innervation loss. A partition analysis revealed a
80% chance of reduced arm ROM when putaminal DAT binding
value was below 2.63 (.47% reduction with respect to median
value of normal subjects).
Average ASA value was 29 (range: 18–35) for PD and 6 for HC
(range: 4–12). ASA and AI indices of both the caudate nucleus
(p = 0.005, RSquare = 0.52) and the putamen (Figure 1; p = 0.001;
RSquare = 0.62) were strongly correlated. This correlation proved
to be statistically significant also when weighted for UPDRSrb and
UPDRS-III scores. Last, no correlation was found between
UPDRSrb and UPDRS-III scores and arm ROM.
Walking at Different Speeds
When walking at different velocities, the range of speeds was
comparable across subjects and PD patients and large enough to
reliably compute a slope line.
No difference was found for lower limbs spatio-temporal gait
parameters (i.e. stride length, stride time and stance) between
patients and controls also when walking at different gait velocities.
Phase shift modulation (slope) was significantly higher in PD
patients than controls (p,0.05, Table 1). All patients were able to
normally modulate all other spatio-temporal gait parameters and
arm ROM (both ipsilateral and contralateral) when walking at
different velocities (Table 1). Interestingly, patients with reduced
arm ROM (,18u) when walking at preferred gait speed showed a
significantly higher capability of modulating upper-lower limb
phase shift which positively correlated with the corresponding
dopaminergic content of the putamen (RSquare = 0.37, p= 0.01)
and caudate nucleus (RSquare = 0.38, p = 0.01). This correlation
was not present if arm ROM was in the range of normality when
walking at preferred gait speed (Figure 2A and B).
Discussion
Some relevant conclusion can be drawn from the present study:
(1.) We confirmed that early-stage PD patients may exhibit normal
spatio-temporal gait parameters [16]. The presence of normal
lower limb locomotor automatisms in subjects with reduced arm
ROM supports the notion that both types of movement may be
differentially organized [17].
(2.) We did not find a linear correlation between arm ROM
reduction and corresponding putaminal dopaminergic depletion.
Rather, we were able to define a cut-off value for dopaminergic
putaminal innervation loss before arm ROM would decrease. (3.)
Inter-limb synergies might be influenced by the imbalance of
dopaminergic striatal tone between the two hemispheres as
shown by the strong correlation between ASA and AI indexes.
These findings question a prominent unihemispheric control of
arm swing during walking. Still, the ASA index should be
carefully interpreted as possibly related to the cut-off itself.
Indeed, in all but two patients with arm ROM unilaterally
reduced, the arm with reduced ROM (according to our
reference value of 18u) was contralateral to the putamen with
Figure 1. ASA significantly correlated to the AI of DAT binding values of the putamen (see, Methods).
doi:10.1371/journal.pone.0051464.g001
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greater dopaminergic innervation loss. (4.) When walking at
different gait velocities, arms with reduced ROM showed an
upper-lower limb coupling (phase shift) influenced by putaminal
dopaminergic innervation. (5.) Locomotor synergies were inde-
pendent of the lateralization of akinetic-rigid symptoms. Such a
discrepancy may provide preliminary evidence for a different
central organization of these entities in PD patients. Indeed,
bradykinesia and rigidity are mainly related to the thalamo-
cortical-basal ganglia loop with strict lateralized organization.
[21,22] Conversely, limbs coordination, especially during auto-
matically performed motor task, may be related to inter-
hemispheric projections of basal ganglia and possibly involve
also mesencephalic centers such as the pedunculopontine
nucleus (PPN) and the reticular system [23].
Limitations in our study must be considered. We arbitrarily
excluded patients with abnormal spatio-temporal parameters at
lower limbs to possibly avoid upper limbs related changes. By
doing this, we limited the patient sample and neglected well
known PD-related gait disturbances, including abnormal timing
of gait and stride-to-stride variability [24]. Another limit of this
study is that PD patients were not drug-naı¨ve. Still, the 3-day
wash-out as well as the several inclusion criteria support the
assumption that the enrolled PD patients well represent an in vivo
model of dopaminergic deficit and allowed us to selectively
investigate the role of intrinsic dopamine and the striatum in
upper limbs locomotor synergies. Last, we cannot exclude in this
study a direct role of a dopaminergic spinal innervation
originating from the dorsal posterior hypothalamus (A11 region)
on locomotor-related movements. Beside local hypothalamic
connections, projections to the neocortex and to the serotonergic
dorsal raphe, A11 neurons descend as the sole source of spinal
dopamine mainly through the dorsolateral funiculus [25] and
innervate most heavily the superficial sensory-related dorsal horn
and the intermediolateral nucleus [26]. A loss of A11 neurons
might eventually alter a possible interplay between dopamine and
serotonin at a spinal level and result in loss of modulation during
locomotion-like activity [27]. The role of the A11 neurons in the
pathophysiology of PD and in locomotion in general, has not
been explicitly tested.
From a anatomo-physiological perspective, the gait-related
pendular motion of upper extremities is a subconsciously and
automatically performed motor task. Inter-limb coordination
remains stable despite changes of limb segment mass, suggesting
independence from peripheral mechanism [28] and it is
maintained across kinematically and kinetically different tasks,
thus possibly related to a common neural control [29].
Descending pathways responsible for the control of locomotor
limb movements, can be ascribed to direct cortical-motoneuronal
input and indirect pathways of the basal ganglia [30,31,32].
Preliminary evidence suggest that dopaminergic neurons play an
important role in the execution of self-determined movements
[33], in the automatic nature of the rhythmic bilateral movements
of the lower-limbs [34] and the persistence of gait execution [9].
This study provides additional information to disentangle a
putative role of dopamine and the striatum in locomotor synergies.
We suggest an interhemispheric rather than unihemispheric
influence on inter-limb coupling. This may be particularly evident
when dopaminergic striatal innervation is greatly reduced (.47%
dopaminergic putaminal innervation loss). Furthermore, when
arm ROM is reduced, the modulation of upper-lower limb
coupling (phase shift) is also related to dopaminergic striatal
content.
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part of
 CONTRAST AGENT EVALUATION
[123I]FP-CIT SPECT in atypical 
degenerative parkinsonism
Parkinson’s disease (PD) is the second most 
common neurodegenerative disorder [1], yet 
early accurate diagnosis remains challenging. 
The estimated prevalence of PD is 0.5–1% in 
those aged 65–69 years and 1–3% in those aged 
80 years [1]. Although the clinical diagnosis of 
PD may be straightforward in cases with a classic 
presentation [2], accurate distinction between PD 
and atypical degenerative parkinsonism (ADP) 
may be difficult, particularly in the early or mild 
stages of disease [3]. In autopsy series, ADP (mul-
tiple system atrophy [MSA], progressive supra-
nuclear palsy [PSP] and corticobasal syndrome 
[CBS]) accounted for half of PD misdiagnoses at 
specialized centers [4,5], while in the community 
Alzheimer’s disease and vascular parkinsonism 
were most common [6,7]. Assessment of the clini-
cal features suggests that an accuracy of 90% 
for PD may be the highest that can be expected 
using the currently available clinical diagnos-
tic criteria. Accurate diagnosis of patients with 
ADP is important to predict the disease course 
and avoid unnecessary medical examinations 
and therapies and their associated side effects, 
safety risks and financial costs. Correct diagno-
sis is also critically important when patients are 
being recruited into clinical trials.
Post-mortem studies demonstrate severe 
reductions in dopamine concentration in the 
striatum of patients with PD, with greater 
reductions in the putamen [8,9]. SPECT with 
[123I]FP-CIT specifically identifies presynap-
tic dopaminergic deficits within the striatum 
[10–13]. Accordingly, an abnormal dopamine 
transporter SPECT image should be regarded 
as exclusion criteria for essential tremor [14], 
dystonic tremor [15] and psychogenic parkin-
sonism [16,17]. In this concise review, we will 
discuss the role of SPECT and [123I]FP-CIT in 
supporting the clinical diagnosis of PD and its 
differential diagnosis with ADP.
[123I]FP-CIT SPECT scans in atypical 
degenerative parkinsonism
Clinically, MSA is a sporadic, progressive neuro-
degenerative disease characterized by varying 
severity of parkinsonian features, cerebellar 
ataxia, autonomic failure and corticospinal 
disorders [18].
PSP presents with early onset postural insta-
bility associated with supranuclear vertical gaze 
impairment, symmetrical akinetic-rigid syndrome 
together with prominent bulbar dysfunction, 
dementia and axial rigidity [19,20].
CBS is characterized by asymmetric akinetic-
rigid parkinsonism and limb dystonia, variably 
associated with cortical signs [21].
The parkinsonian types of MSA (MSA-P) and 
PSP (PSP-P) can be very difficult to distinguish 
from PD before disease-specific signs and symp-
toms occur. This also applies to CBS because 
of its marked asymmetrical akinetic-rigid syn-
drome before apraxia, myoclonus and cognitive 
problems become evident. Correct differentia-
tion is important as PD has a better prognosis 
than ADP syndromes and responds better to a 
symptomatic treatment [22].
In PD the decrease in [123I]FP-CIT binding 
usually occurs in the dorsal putamen contralat-
eral to the side of the neurological symptoms, 
in time progressing anteriorly and ipsilaterally 
(FIGURE 1) [12,14,23].
One of the most widely used techniques to support the clinical diagnosis of Parkinson’s disease is the 
SPECT scan with [123I]FP-CIT. This tracer binds reversibly and visualizes the striatal presynaptic dopamine 
transporters. Several uncertainties remain on the value of [123I]FP-CIT and SPECT in atypical degenerative 
parkinsonian syndromes. In this concise review, we discuss the contribution of SPECT and [123I]FP-CIT in 
supporting the clinical diagnosis of Parkinson’s disease and their role in the differential diagnosis of 
Parkinson’s disease and atypical degenerative parkinsonism. The chemistry, pharmacodynamics and 
pharmacokinetics of [123I]FP-CIT are also discussed.
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Several studies investigated PD and ADP 
by means of [123I]FP-CIT and SPECT scans. 
However, only few specifically established the 
value of [123I]FP-CIT in setting a differential 
diagnosis (TABLE 1).
The amount and pattern of reduced striatal 
DAT binding in MSA have been demonstrated 
to be within the range of PD. However, asym-
metry of DAT binding loss tends to be more 
pronounced in PD and the progression of 
dopaminergic innervation loss is faster in MSA 
compared with PD [24,25]. In a recent study that 
compares the accuracy of dual-tracer DAT and 
perfusion SPECT imaging in the differential 
diagnosis of parkinsonism using template-based 
discriminant ana lysis [26], no reduction of MSA 
versus PD was noted. In contrast to what was 
reported by Scherfler and colleagues, demon-
strating differential [123I]E-CIT binding capac-
ity between PD and MSA [27], the aforemen-
tioned study could not detect differences even 
at the least stringent threshold (p = 0.05 uncor-
rected). The reverse contrast (PD < MSA) 
demonstrated a decreased binding in the left 
posterior putamen. However, El Fakhry and 
colleagues reported lower striatal binding val-
ues in PD (55%) and MSA (23%) compared 
with normal controls (p < 0.01) and lower val-
ues in PD compared with MSA (p < 0.05) [28]. 
Asymmetry index was greater for PD than for 
MSA and controls in both the caudate nucleus 
and the putamen (p < 0.05). In addition, there 
was a significantly decreased perfusion in the left 
and right nucleus lentiformis in MSA compared 
with PD and controls (p < 0.05).
A reduction of [123I]E-CIT uptake in the mid-
brain appears to separate patients with clinically 
fully developed MSA-P or PSP from patients 
with PD [23,27,29]. Indeed, a reduced midbrain 
[123I]E-CIT uptake was found in patients with 
MSA-P and allowed a correct classification of 
95% of MSA-P and PD patients [23,30]. Finally, 
clinically pure forms of MSA-C (cerebellar 
variant) may show a DAT binding loss but less 
compared with MSA-P or PD [31].
Antonini and colleagues reported a greater 
DAT reduction in patients with PSP (0.51 ± 0.39; 
p < 0.01) compared with MSA-P patients 
(0.70 ± 0.33) or PD patients (0.95 ± 0.38) [32]. 
No difference was found between patients with 
MSA and PD. Putamen/caudate ratios were 
greater in PSP (0.83 ± 0.12; p < 0.01) than in 
PD patients (0.51 ± 0.11), suggesting a more-
uniform involvement of dopamine nerve ter-
minals in both caudate nucleus and putamen. 
Van Laere and colleagues also demonstrated a 
greater involvement of the caudate heads in PSP 
patients, although when directly contrasted with 
PD patients, a difference was found in the left 
striatum only at a p = 0.05 uncorrected level [26].
DAT loss in CBS is in the same range as that 
in PD patients [33–35]; but more asymmetrical and 
less pronounced than in MSA and PSP patients 
[34]. In CBS, unlike PSP or PD, unilateral bal-
anced (caudate/putamen) reduction in tracer 
uptake has been observed [33]. DAT binding may 
result occasionally within the normal range in 
patients with CBS [35–37]. The low sensitivity and 
specificity of [123I]FP-CIT for the diagnosis of 
CBS also relies on the pathological and clinical 
heterogeneity of this syndrome (FIGURE 2) [37,38] .
Overall, a meta-ana lysis of diagnostic accu-
racy on SPECT in parkinsonian syndromes 
[39] revealed, for presynaptic tracers in gen-
eral, a moderate to high sensitivity but a low 
specificity in differentiating PD from MSA and 
PSP (pooled odds ratio with 95% CI was 2). 
Similarly, presynaptic tracers showed a very 
HC (F)
Age: 52
Caudate L: 5.93; R: 5.93
Putamen L: 5.71; R: 5.60
P  (  )
Age: 72
  : 5
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Putamen L: 2.63; R: 1.20
P  (F )
Age: 56
  : 3
H  : 2
Caudate L:  .9 ; R:  .06
Putamen L: 3.07; R: 1. 6
Figure 1. [123I]FP-CIT of healthy controls and Parkinson’s disease subjects. [123I]FP-CIT SPECT 
images and binding values of healthy subjects and patients with Parkinson’s disease or atypical 
degenerative parkinsonism.
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high sensitivity (78–100%) but a low specific-
ity (0–33%) in discriminating between MSA 
and PSP (pooled odds ratio with 95% CI was 2).
In conclusion, [123I]FP-CIT and SPECT have 
little value in discriminating between ADPs in 
routine clinical practice and they should be 
used with great care when differentiating ADP 
from PD, as only hints towards a more accurate 
clinical diagnosis can be obtained. On the other 
hand, a normal result is considered inconsistent 
with a clinical diagnosis of PD or ADP [39,40].
Postsynaptic dopamine receptor imaging, in 
addition to presynaptic dopamine transporter 
imaging, may be necessary, together with clinical 
reassessment and follow-up imaging, to improve 
diagnostic accuracy in PD and ADP [41]. The 
Table 1. Summary of [123I]FP-CIT findings in subjects with atypical degenerative parkinsonism.
Study (year) Tracer Clinical diagnosis Imaging findings Ref.
Benamer et al. 
(2000) 
[123I]FP-CIT PD (n = 145), MSA (n = 2), 
PSP (n = 10), ET (n = 33), 
HC (n = 38)
Clear visual differentiation between ET and HC vs PD and 
atypical parkinsonism. No differences between atypical 
parkinsonism and PD
[10]
Antonini et al. 
(2003) 
[123I]FP-CIT PD (n = 70), MSA (n = 10), 
PSP (n = 10), HC (n = 12)
Striatal binding reduced in PD, MSA and PSP vs HC
Greater and more uniform bilateral binding loss in PSP vs 
PD and MSA
[32]
Plotkin et al. (2005) [123I]FP-CIT
[123I] IBZM
PD (n = 25), MSA (n = 13), 
PSP (n = 8), DLB (n = 6), 
CBS (n = 9), ET (n = 11)
[123I]FP-CIT: all ET subjects had normal scans
No significant differences among atypical parkinsonism 
CBS patients showed a significantly lower asymmetry index 
for striatum and putamen
[123I] IBZM: no difference between ET and PD. Lower 
binding values in MSA, PSP and CBD in comparison with 
PD, ET and DLB but no differences between ADPs
[30]
El Fakhri et al. 
(2006) 
[123I]FP-CIT
[99Tc]ECD
PD (n = 5), MSA (n = 5), 
HC n = 9)
[123I]FP-CIT: significant binding loss in PD and MSA vs HC
Greater reduction in PD vs MSA
[99Tc]ECD-CIT: no significant regional perfusion differences 
between PD and HC
Reduced bilateral perfusion in caudate nucleus and nucleus 
lentiformis in MSA when compared with PD and HC
[28]
Koch et al. (2007) [123I]FP-CIT
[123I] IBZM 
PD (n = 69), MSA (n = 18), 
HC (n = 13)
[123I]FP-CIT: lower binding in PD vs atypical parkinsonism
[123I] IBZM: higher D2 receptor binding in PD vs atypical 
parkinsonism
No differentiation between atypical parkinsonism at 
imaging ana lysis
[65]
Vlaar et al. (2008) [123I]FP-CIT
[123I] IBZM
PD (n  = 127), ET (n = 22), 
MSA (n = 17), PSP (n = 8), 
CBD (n = 1)
The differentiation between PD and atypical parkinsonism 
by both tracers scored relatively low accuracy. The 
combination of the two only minimally increased accuracy
[40]
Mo et al. (2010) [123I]FP-CIT
[123I] IBZM
PD (n = 104), MSA (n = 7), 
PSP (n = 3)
[123I]FP-CIT: significantly reduced binding in PD, MSA and 
PSP vs HC. No statistical binding differences between PD 
and atypical parkinsonism
[123I] IBZM: no significant differences in postsynaptic uptake 
ratios between PD and controls, and PD and atypical 
parkinsonism
[53]
Cilia et al. (2011) [123I]FP-CIT PD (n = 37), CBS (n = 36), 
HC (n = 24)
More uniform reduction throughout the striatum and 
greater hemispheric asymmetry (for the caudate nucleus) in 
CBS vs PD
On average, CBS patients showed reduced binding values 
vs HC and higher asymmetry indices  in the caudate 
nucleus and putamen and similar caudate-to-putamen ratio 
in CBS vs HC
Normal binding values in four CBS patients
[37]
Südmeyer et al. 
(2011)
[123I]FP-CIT
[123I] IBZM
[123I]MIBG
PD (n = 31), MSA (n = 11), 
PSP (n = 6)
The combined use of tracers reached distinguished atypical 
parkinsonism from PD with a sensitivity of 94%, specificity 
of 94% (test accuracy 94%), positive predictive value of 
89% and negative predictive value of 97%
Differential diagnosis within atypical parkinsonism was not 
reported
[63]
ADP: Atypical degenerative parkinsonism; CBD: Corticobasal degeneration; CBS: Corticobasal syndrome; DLB: Dementia with Lewy bodies; ET: Essential tremor; 
HC: Healthy control; MSA: Multiple system atrophy; PD: Parkinson’s disease; PSP: Progressive supranuclear palsy.
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most widely applied radiotracer for imaging D2 
receptors with SPECT is [123I]iodobenzamide 
([123I]IBZM) [42,43]. Postsynaptic receptor den-
sity is normal or upregulated in early PD but 
invariably decreased in ADP [44–47]. Along with 
PD progression, binding values of PD patients 
are still in the range of control subjects, possibly 
due to a decline in the presynaptic dopaminer-
gic drive, which results in dopamine receptor 
upregulation [48–51]. The preserved D2/D3 recep-
tor availability is a prerequisite for the response 
to l-Dopa therapy [52]. The combination 
of pre- ([123I]FP-CIT) and post-synaptic 
([123I]IBZM) dopamine SPECT can serve as an 
indicator for excluding ADP with a reasonably 
high accuracy of 85%, especially in early diag-
nosed drug-naive PD patients [23,53]. Compared 
with [123I]FP-CIT [30], [123I]IBZM has a dis-
tinctly lower ability to detect alterations of the 
dopaminergic system, and therefore should only 
be used as an additional examination to further 
corroborate a potential sufferer of ADP. [123I]
IBZM binding is variably decreased in ADPs 
and cannot discriminate between them [40]. As 
a cautious suggestion, [123I]IBZM SPECT may 
more often result in a normal range in CBS than 
in MSA or PSP [34]. The diagnostic performance 
might be substantially improved with the use of 
a D2/D3 receptor radioligand and PET [54].
Metabolic and perfusion studies using PET 
or SPECT have also shown some value in the 
differential diagnosis of ADP. In particular, 
disease-related spatial covariance patterns 
identified a marked bilateral reduction in the 
lentiform nuclei and the cerebellum in MSA. 
By contrast, PSP is characterized by the pres-
ence of metabolic decrements in midline frontal 
regions and in the brainstem. The distinguish-
ing feature of the pattern of glucose metabo-
lism in CBS is the asymmetrical distribution 
of radiotracer uptake with a relative metabolic 
reduction in many cortical areas, the insula and 
in the basal ganglia contralateral to the most 
affected side [55,56].
However, the overall diagnostic accuracy of 
metabolic and perfusion studies seems rather 
poor in a single patient. When comparing 
[123I] IBZM SPECT and [18F]FDG PET in neu-
rodegenerative parkinsonism, it is clear that inter-
rater agreement of visual ana lysis is substantial in 
both methods [57]. However, findings of either 
are discordant in a significant number of cases.
It is an open issue which nuclear medicine 
examination best relates to clinical course. 
Clinical tests and follow-up examinations, as 
well as morphologic information (e.g., MRI), 
are still necessary as additional diagnostic tools 
to discriminate within ADP [46,58,59].
As an alternative, cardiac imaging with 
([123I] MIBG) has demonstrated changes con-
sistent with heart denervation in patients with 
PD that are not present in patients with MSA or 
PSP [60]. However, the use of this tracer is lim-
ited because of insufficient sensitivity in patients 
with short disease duration [61]. Furthermore, 
by applying a PET radioligand, cardiac sympa-
thetic denervation was found to occur not only 
in PD but also in other movement disorders, 
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Figure 2. [123I]FP-CIT of healthy controls and atypical degenerative 
parkinsonisms.
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such as MSA and PSP [62]. This finding implies 
that scintigraphic detection of cardiac sympa-
thetic denervation cannot be used indepen-
dently to discriminate idiopathic PD from 
other movement disorders, such as MSA and 
PSP. Furthermore, cardiac sympathetic denerva-
tion was not correlated with striatal denervation 
(measured with a PET-compound for vesicu-
lar monoamine transporter, which is supposed 
to be of at least similar diagnostic values as 
the DAT radiotracers). This suggests that the 
patho physiologic processes underlying cardiac 
denervation and striatal denervation occur 
independently in patients with parkinsonian 
syndromes [62].
The combined use of [123I]MIBG and 
[123I]FP-CIT or [123I]IBZM signif icantly 
improved diagnostic accuracy in PD versus 
ADP reaching a sensitivity of 94%, specific-
ity of 94%, positive predictive value of 89% 
and negative predictive value of 97%. However, 
even the combination of these tracers was not 
able to discriminate between PSP and MSA 
with more success than clinical follow-up at 
2 years [63].
Although disease-related differences in the 
pattern of nigrostriatal degeneration of PD and 
ADP are present [64], DAT imaging does not 
significantly improve diagnostic accuracy in all 
cases and it is of little help in the differential 
diagnosis between ADP [25]. The best imaging 
approach to clarify whether the cause of pre-
synaptic dopaminergic loss is PD or ADP is a 
combined radiotracer or multimodal approach 
including dopamine D2 receptor imaging [30,65], 
MRI techniques [66,67] and eventually cardiac 
imaging of the sympathetic nervous system [62].
Finally, in the absence of histopathological 
material nearly all imaging studies have used 
clinical diagnoses as the gold standards so 
far, which may not always be accurate. Given 
the high rate of clinical misdiagnosis [4,5] this 
should be regarded as the main bias of all such 
studies.
Introduction to the compound
  Chemistry
[123I]FP-CIT (ioflupane) is commercially avail-
able as DaTSCAN in many European countries 
(e.g., in Germany since 2000) and also in the 
USA since 2011. It is delivered as a pyrogen-free 
radiopharmaceutical for intravenous injection in 
single-use vials. It is a cocaine analog substance 
and tropane derivative (FIGURE 3).
Iodine-123 is a cyclotron-produced, J-emit-
ting radionuclide with a main energy level of 
159 keV and a physical half-life of 13.2 h. The 
active drug compound is N-Z-fluoropropyl-
2E-carbomethoxy-3E-(4-[123I]iodophenyl)nor-
tropane. In vitro, ioflupane binds reversibly to 
the human recombinant DAT with IC50 ranging 
from 0.71 to 1.67 nM as examined using rat stri-
atal tissue homogenates by displacement of the 
radiotracer [3H]-WIN 35,428 [68–70]. Potency 
of ioflupane was much greater than for cocaine 
(IC50: 89.1 nM) and similar to E-CIT (IC50: 
1.24 nM). High binding affinity of ioflupane 
in human striatum has been shown autoradio-
graphically using a C-11 labeled compound [71]. 
Binding was low in the cortex and other brain 
regions, and in the thalamus it was 10% of bind-
ing in the putamen. Approximately 80–90% of 
the striatal binding was blocked by the DAT 
inhibitor GBR 12,909; the inhibition constant 
was Ki = 0.62 nM. High specificity to the pre-
synaptic DAT was demonstrated by competition 
studies with GBR 12,909, the serotonin reup-
take inhibitor citalopram and the norepineph-
rine reuptake inhibitor desipramine in post-mor-
tem human brain slices exposed to radiolabeled 
ioflupane. Autoradiographically, binding was at 
high concentrations in the DAT-rich striatum; 
(in other words, the caudate nucleus and the 
putamen) and this binding to the striatum was 
abolished in the presence of high concentrations 
of GBR 12,909.
The recommended dosage of [123I]FP-CIT is 
111–185 MBq (3–5 mCi), typically 185 MBq 
(5 Ci). In our own experience, no doses less 
than 150 MBq (4 mCi) should be applied, 
since lower amounts of activity may have an 
impact on scan quality and hence, diagnostic 
performance.
  Pharmacodynamics
Overall, imaging agents contain only a small 
quantity of active compound so that no 
pharmaco logic effects are expected. In general, 
the DAT-binding tropanes are good markers for 
the integrity of the nigrostriatal systems. Ex vivo 
studies in an animal lesion model using both 
an analog of levodopa and a DAT-radiotracer 
revealed that the uptake of [18F]FDOPA and 
[18F]CFT correlated well with the density of 
FH2CH2CH2CN COOCH3
123I
Figure 3. [123I]FP-CIT.
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dopaminergic fibers [72]. This indicated a high 
sensitivity of both radiotracers in PD. However, 
[18F]FDOPA demonstrated a higher unspecific 
uptake that was probably due to extensive com-
pensatory metabolism. So it seems that this 
tracer was less sensitive than the DAT-tracer 
[18F]CFT in detecting nigro striatal degenera-
tion [72]. Since the uptake of the latter was heav-
ily reduced in degeneration stage two, a down-
regulation of DAT was hypothesized. Another 
lesion study in rats using [125I]E-CIT and [14C]
L-DOPA provides similar results, indicating 
that the marker of the decarboxylase underes-
timated the decrease of dopaminergic neurons 
and that DAT levels more precisely reflected 
the decrease [73]. Such different detection sen-
sitivities of radiotracers for DAT, the vesicular 
monoamine transporters (VMAT2) and [18F]
FDOPA in (early) PD [74] were also predicted 
in humans. Other head-to-head comparisons 
in humans did not reveal any significant differ-
ences in the diagnostic utilities of radiotracers 
for DAT, the vesicular monoamine transporters 
(VMAT2) or [18F]FDOPA [13].
In addition, there are no differences among 
tropane derivatives in detecting early dopa-
minergic degeneration (FP-CIT; E-CIT; IPT; 
TRODAT-1 [75–78]). A direct comparison of 
[123I]FP-CIT versus [123I]E-CIT revealed similar 
capabilities for the detection of dopaminergic 
degeneration [79].
  Pharmacokinetics & metabolism
The pharmacokinetics of [123I]FP-CIT were 
studied by monitoring radioactivity following 
intravenous injection and whole-body scintig-
raphy. Such biodistribution studies revealed 
that 5% of the administered radioactivity 
remains in whole blood 5 min after the injec-
tion and 7% of injected radioactivity enters the 
brain 10 min after the injection. Radioactivity 
in the brain decreases to 3% after 5 h. The 
striatum-to-background ratio is relatively con-
stant between 3 and 6 h after the injection, 
meaning that clinical imaging is feasible with 
comparative results during this time window. 
This is a major advantage of [123I]FP-CIT over 
other tropane-based radiotracers, in particular 
[123I]E-CIT, which reaches an ‘equilibrium’ 
after 24 h for DAT-rich regions. For [123I]
FP-CIT, approximately 30% of the whole 
brain radioactivity was attributed to striatal 
uptake. The biodistribution, metabolism and 
dosimetry of ioflupane in nonhuman primates 
and in humans are further described in several 
papers [71,80–83].
  Drug interactions
Based on published data, it is likely that sev-
eral drugs of abuse, including cocaine, amphet-
amines, modafinil, certain antidepressants (e.g., 
mazindol, bupropion and radafaxine, among 
others), adrenergic agents (e.g., phenylephrine 
and norepinephrine) and the anticholinergic 
agent benzatropine, influence the visual inter-
pretation and quantification of [123I]FP-CIT 
SPECT scans in routine clinical studies.
Ideally, such medications should be with-
drawn, before the administration of the radio-
tracer, at a time five-times greater that the drug’s 
biological half- life [84]. The decision to with-
draw any medication must always be made by 
the specialist in charge of the patient’s care, bal-
ancing the potential risks of such a withdrawal.
Antiparkinsonian medications (i.e., levodopa, 
dopamine agonists, N-methyl-d-aspartate 
receptor blockers, monoamine oxidase-B inhibi-
tors and catechol-O-methyltransferase inhibi-
tors) taken at standard doses do not markedly 
affect dopamine transporter binding, and 
therefore they need not be withdrawn before 
dopaminergic imaging [84,85].
Interestingly, one study showed a significant 
higher binding in patients with ADP without 
antiparkinsonian medication in comparison to 
subjects in drugs-on state [23].
  Data acquisition & ana lysis
A prerequisite for fully utilizing the diagnostic 
potential of DaTSCAN imaging is, however, 
good quality control and standardization of 
the entire procedure, from patient preparation 
through to positioning, J camera specifications, 
acquisition, reconstruction parameters and 
quality control of the acquired data. In addition 
data should be analyzed and reported accord-
ing to guidelines (i.e., European Association 
of Nuclear Medicine [84] and the guidelines of 
the Society of Nuclear Medicine). Technical 
issues with regard to data acquisition comprise 
correct field of view, rotational radius, energy 
window set at the photopeak, additional scatter 
windows (if applicable), matrix size and zoom 
factor, among others. Strict standardizations of 
acquisition time after radiotracer injection and 
collection of sufficient numbers of total counts 
within the acquisition time also have to be con-
sidered. After reviewing the projection data 
(i.e., for motion artifacts), images are processed 
with distinct reconstruction methods (iterative 
reconstruction or filtered back-projection) and 
filtering (e.g., with a low pass filter). Employing 
the correct filter is mandatory for either visual 
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or quantitative readings. Attenuation correction 
is recommended, either with simultaneously or 
sequentially acquired transmission scans, or cal-
culated, as with a correction matrix, according 
to Chang [86].
For display, images are reformatted into 
slices in three planes (axial, coronal and sagit-
tal). Reorientation makes visual interpretation 
easier and is essential when semi-quantification 
is used (not least to ensure the right place-
ment of the reference region). The anterior 
commissure-posterior commissure line repre-
sents a good anatomical standard here as it is 
used for brain MRI. A simultaneously acquired 
CT scan or, alternatively, coregistration with 
(individual) MRI by commercial available soft-
ware (e.g., HERMES MultiModality, Hermes 
Medical Solutions, Stockholm, Sweden) will 
allow precise re-alignment of the head.
Visual assessment is robust in detecting pre-
synaptic DAT binding. However, in visually 
uncertain cases and for intergroup, as well as for 
interinstitutional comparisons, semi quantitative 
approaches using regions of interest (ROIs) 
might help and have been recommended by 
nuclear medicine associations to be incorpo-
rated in the routine work-up of DAT-SPECT. 
With semi-quantification, striatal binding ratios 
(specific striatal binding) are calculated by com-
paring the activity in the target region with the 
activity in a reference region (with a very low 
DAT-density) according to listed formula (BOX 1).
Reference region should conventionally refer 
to the occipital cortex for [123I]FP-CIT. Other 
parameters are described in BOX 1.
ROIs are manually drawn on to one or more 
slices (usually three or four adjacent slides) with 
the highest striatal activity. This method is sim-
ple and provides a quantitative measure to allow 
comparisons of healthy reference data (where 
an age-dependent decline in healthy volunteers 
always has to be considered) but interobserver 
variability is considerable (due to variability 
in ROI placement). Therefore, it is important 
to standardize realignment (using predefined 
ROIs). Here, coregistration with individual 
MRI for delineation of striatal and reference 
volumes of interest offers the most accurate 
manual results [87].
Besides these observer-dependent approaches, 
fully-automated image ana lysis techniques are 
under validation in the clinical setting and have 
the potential as tools to improve the diagnos-
tic accuracy and confidence in DAT-SPECT 
in patients who have parkinsonian features. 
Examples of these more advanced automated sys-
tems using volumes of interest, and voxel-based 
mathematical systems are DATQUANT™ (GE 
Healthcare, WI, USA), EXINI dat™ (EXINI 
Diagnostics AB, Lund, Sweden), and a modified 
version of the Brain Analysis Software (BRASS, 
BRASS-DaT, Hermes Medical Solutions, 
Stockholm, Sweden). They are all capable of 
producing more objective, observer-indepen-
dent results and are faster compared with indi-
vidual ROI/volume-of-interest-based methods. 
The voxel-based systems often use statistical 
parametric mapping (Wellcome Department 
of Cognitive Neurology, University College 
London, UK) that runs on a MATLAB® plat-
form (The MathWorks Inc., MA, USA); how-
ever, this is for scientific purposes and not in 
routine clinical practice.
  Safety & tolerability
No adverse event has been directly correlated 
with the tracer itself. However, several symptoms 
(e.g., headache, flu-like symptoms, injection site 
bleeding, vertigo and parasthesia) were described 
to be possibly or probably due to [123I]FP-CIT 
injection [10].
  Cost–effectiveness
[123I]FP-CIT SPECT scans proved to be eco-
nomically advantageous in the diagnostic work-
up of patients with uncertain parkinsonism 
(including essential tremor), especially when 
total indirect treatment costs over time were cal-
culated [88,89]. No studies specifically addressed 
cost–effectiveness of [123I]FP-CIT SPECT for 
Box 1. Binding ratio formulas.
Striatal binding ratio Mean counts of reference (background) ROI
Mean counts of striatal ROI mean counts of reference (background) ROI= -
Putamen to caudate ratio Specific striatal binding
Specific striatal binding
caudate
putamen- - =
Asymmetry Specific striatal binding specific striatal binding
Specific striatal binding specific striatal binding 2
right striatum left striatum
right striatum left striatum= #
+
-
 
ROI: Region of interest.
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ADP. Cost–effectiveness may also derive from 
the incorrect screening of suitable candidates 
for drug trials or complex surgical procedures 
(e.g., deep brain stimulation) that may not be 
effective for ADP.
Conclusion & future perspective
Differentiating PD from ADP solely on [123I]
FP-CIT imaging is still a challenge. Some sug-
gestions may derive from asymmetry and diffu-
sion of dopaminergic deficit or from targeting 
the brainstem. No additional value to the clini-
cal experience is added instead in discriminat-
ing between ADPs. This result derives also in 
part from the limited number of patients with 
ADP investigated and from the uncertainties of 
clinical diagnosis still used as the reference in 
the absence of anatomopathological findings. 
The combination of several available SPECT 
tracers may not necessarily enhance specificity 
and sensitivity in discriminating between 
ADPs. Nowadays, imaging should not be con-
sidered as a replacement for a thorough clinical 
investigation and patients should be referred to 
movement disorder specialists. However, [123I]
FP-CIT and SPECT imaging has been proven 
to be a safe and effective tool to investigate 
dopaminergic innervation and help exclude 
diseases without such an innervation loss.
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Dopaminergic Striatal Innervation Predicts Interlimb
Transfer of a Visuomotor Skill
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We investigatedwhether dopamine influences the rate of adaptation to a visuomotor distortion and the transfer of this learning from the
right to the left limb in human subjects. We thus studied patients with Parkinson disease as a putative in vivo model of dopaminergic
denervation. Despite normal adaptation rates, patients showed a reduced transfer compared with age-matched healthy controls. The
magnitude of the transfer, but not of the adaptation rate, was positively predicted by the values of dopamine-transporter binding of the
right caudate and putamen.We conclude that striatal dopaminergic activity plays an important role in the transfer of visuomotor skills.
Introduction
Motor learning relies on the intact function of dopaminergic
transmission (Knowlton et al., 1996; Seidler et al., 2006; Seidler
and Noll, 2008; Karabanov et al., 2010). In particular, dopamine
neurons play an important role in coding reinforcement predic-
tion errors, a key signal in many learning models (Sutton and
Barto, 1998; Maia, 2009). Prediction errors are used to learn the
values of states, state-action pairs, or both, which are then used to
select optimal actions (Sutton and Barto, 1998). At the cellular
and synaptic level, such learning is thought to occur through
long-term changes in synaptic strength at striatal synapses, with
dopamine release as an essential signaling event starting the pro-
cess (Montague et al., 2004; Calabresi et al., 2007).
Adaptation of reaching movements to visuomotor rotation is
a type of learning that can take place implicitly. During this learn-
ing process, a new internalmodel ormemory is gradually formed,
while the discrepancy between the desired and the executed tra-
jectory gradually diminished (Krakauer, 2009). Several studies
have suggested a right-hemisphere dominance in the acquisition
of this motor skill (Ghilardi et al., 2000; Huber et al., 2004), but
the role of dopamine and its basal ganglia innervation in visuo-
motor adaptation has been poorly investigated. Previous studies
have shown that adaptation but not retention is normal in pa-
tients with Parkinson disease (PD) (Marinelli et al., 2009; Be´dard
and Sanes, 2011; Venkatakrishnan et al., 2011), but have not
addressed the role of dopamine in this task.However, the existing
evidence in normal subjects suggests that the striatum plays an
important role in the formation and retrieval of this motor skill
(Ghilardi et al., 2000; Seidler et al., 2006; Seidler and Noll, 2008).
When learning is accomplished with one limb through task
repetition, the ability to perform the same task with the opposite,
untrained limb can also improve. This process is referred to in-
terlimb transfer and has been shown to apply to visuomotor ad-
aptation (Sainburg and Wang, 2002). Interlimb transfer implies
that the limb-specific motor memory, stored during adaptation,
can be retrieved and applied to the other limb with different
dynamic characteristics. As reported in several studies, the corpus
callosum is likely involved in this process (for review, see Hals-
band and Lange, 2006). However, given their important role in
motor learning, dopamine and the striatum could be also in-
volved in such a skill, but their function has not been directly
assessed.
The aim of this study is to determine whether the adaptation to
visuomotor rotation and its transfer to the untrained hand depend
on dopamine levels. Thus, we investigated the time course of adap-
tation to a rotated display with the right hand and its transfer to the
left hand in drug-naive patients with PD and in age-matched con-
trols. We then correlated the indices of learning and transfer to
dopaminergic innervation asmeasuredby [123I]N-!-fluoropropyl-
2"-carbomethoxy-3"-(4-iodophenyl)tropane (FP-CIT)and single-
photon computed tomography (SPECT) (Isaias et al., 2007).
Materials andMethods
Subjects.We tested 11 patients with PD (five males; median age, 52 years;
range, 38–66 years) and a control group of 10 neurologically intact
adults (three males; median age, 52 years; range, 42–79 years). Median
age of PD patients at motor symptoms onset was 47 years (33–64 years).
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All subjects were right-handed, as assessed by a modified Edinburgh
handedness inventory.
The diagnosis of PDwasmade according to the UK Parkinson Disease
Brain Bank criteria and patients evaluated with the Unified Parkinson
Disease Rating Scale motor part (UPDRS-III). Two additional UPDRS
sub-subscores were calculated (Isaias et al., 2007). Median UPDRS-III
score was 12 (range, 6–20). Median akinetic-rigid score (UPDRS-AK)
was 5 (range, 2–11) and median UPDRS tremor score (UPDRS-T) was 1
(range, 0–2).
Clinical inclusion criteria for subjects with PD were as follows: (1)
UPDRS part I score of 0; (2)UPDRS-T score!3; (3) disease duration!5
years; (4) Hoehn and Yahr scale, stage 2; (5) drug naive (patients had
never been treated with any antiparkinsonian drugs); (6) no psychiatric
disorders or other neurological diseases other than PD; and (7) absence
of any signs indicative for atypical parkinsonism (e.g., gaze abnormali-
ties, autonomic dysfunction, psychiatric disturbances, etc.).
All subjects (patients and controls) had no cognitive decline as well as
no deficit in visual attention, task switching, memory, or learning strat-
egies, as assessed by the Mini-Mental State examination, Clock Drawing
Test, Frontal Assessment Battery, Corsi block-tapping task, Corsi supras-
pan learning task, Corsi Recall, and Trail Making Test (A, B, and A-B).
An MRI was also performed and only subjects with normal results (i.e.,
no sign of white matter lesion or atrophy) were enrolled in the study.
MRIs were performed within 6 months from subjects’ enrollment. None
of the controls had a history of neurological disorders, head trauma with
loss of consciousness, epilepsy, brain surgery, systemic illness, or exces-
sive drug or alcohol consumption at any time during their life. Partici-
pants were instructed not to drink any beverages containing caffeine or
alcohol during the 24 h before the experiment. The local institutional
review board approved the study.
Task and experimental design. The motor tasks have been extensively
described in previous papers (Ghilardi et al., 2000; Huber et al., 2004;
Marinelli et al., 2009). Briefly, subjects moved a cursor with their domi-
nant or nondominant hand on a digitizing tablet and performed out-
and-back movements toward one of eight targets presented on the
computer screen every 1.5 s. Vision of both the hand and arm was pre-
vented by an opaque panel, but the position of the cursor on the screen
was always visible. Targets were positioned 4 cm from a common starting
point and were presented in blocks of 48 (block duration, 72 s). Hand
trajectory was sampled at 200 Hz.
We used two tasks: a baseline motor task, in which the cursor position
on the screen and the hand position on the tablet corresponded; and a
visuomotor adaptation task (ROT), in which the cursor position on the
screen was rotated 30° counterclockwise to the actual hand movement.
In the main experiment, after familiarization with the apparatus, sub-
jects performed two blocks of baseline condition with each hand; no
visual distortion was applied. Subsequently, they performed 10 blocks of
ROT with the dominant (right) hand, followed by three blocks of ROT
with the nondominant (left) hand.
Three weeks later, seven patients (six women; median age, 50 years;
range, 39–57 years) and eight normal controls (five women; median age,
58.5 years; range, 42–66 years) were retested, in the same clinical condi-
tions, with one block (48 movements) of the baseline motor task per-
formed with the left hand to assess long-term aftereffects.
Behavioral data analysis. In this study, we were interested in describing
the process of adaptation to the imposed cursor distortion. Therefore, we
first measured the initial planning of the movement direction as direc-
tional error at peak velocity, which is the difference between the target
direction and the movement direction at peak velocity. For each hand,
directional errors in the ROT blocks were normalized (DirErrVnorm) by
subtracting the mean error in the corresponding baseline motor task
where no rotation was applied.
We then computed the average percentage adaptation to the applied
distortion for each ROT block as: percentage adaptation " 100 * (1 #
DirErrVnorm/30).We thenmeasured themovement curvature to inves-
tigate the degree of online correction as the absolute difference between
the directional error at peak velocity and that at the reversal point.
To measure the degree of total adaptation achieved with the right
hand, we computed the difference in percentage adaptation between the
first and last block. The same differencewas computed for themovement
curvature.
Right-to-left interlimb transfer wasmeasured as the percentage differ-
ence between the last adaptation block with the right hand and the first
with the left hand for both indices.
We assessed differences in the rate of adaptationwith the right hand, as
well as changes in curvature, by performing a mixed-model ANOVA
(!" 0.05) on both variables with Group (PD, controls) as the between-
subject factor and Block (1–10) as the within-subject factor.
The between-group differences in the degree of total adaptation
achieved and the difference in curvature, as well as for the interlimb
transfer of both these variables, were assessed using a one-way ANOVA
with Group as main factor.
SPECT data acquisition and reconstruction. SPECT data acquisition
and reconstruction has been described in detail previously (Isaias et al.,
2010). In brief, dopamine-transporter (DAT) values weremeasured with
SPECT with FP-CIT. Intravenous administration of 110–185 MBq of
123I-FP-CIT (DaTSCAN; GE Healthcare) was performed 30–40 min af-
ter thyroid blockade (10–15 mg of Lugol solution per os) in all patients.
Data were compared with data from a group of 15 healthy subjects
matched for age (mean age, 62 years;$9 SD; range, 44–68 years) and sex
Figure 1. Top left, Target array with three trajectories representative of initial (1), interme-
diate (2), and complete (3) levels of adaptation. Bottom left, Illustration of directional error and
curvature at an initial level of adaptation (see line 1, top left panel). a, b, Time course of
adaptation (basedondirectional errors at thepeak velocity;a) and curvature (b) as a function of
blocks for the right hand and for transfer to the left hand in patient and control groups. Bars
represent SEs.
Table 1. Anatomic locations with side, spatial extent of cluster in voxels (Ke), t
score, and Z score of striatal areas showing significant values, MNI coordinates
Side Cluster size t value Z score
MNI coordinates
(x, y, z)
Two-samples t test: PD versus HC
Putamen R 1844 13.56 6.95 32, 0, 0
Caudate R Subcluster 9.58 5.95 16, 12, 10
Ventral striatum R Subcluster 4.95 4.61 18, 20,#6
Putamen L 1575 11.14 6.39 #28,#6,#2
Caudate L Subcluster 6.58 4,84 #14, 20,#8
Covariance analysis of adaption
transfer score
Caudate R 76 3.7 3.23 16, 8, 14
Putamen R 219 3.0 2.71 32, 4,#2
L, Left; R, right.
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(four males). Brain SPECT was performed 3–4 h later by means of a
dedicated triple detector gamma-camera (Prism 3000; Philips) equipped
with low-energy, ultra-high-resolution fan beam collimators (four sub-
sets of acquisitions; matrix size, 128! 128; radius of rotation, 12.9–13.9
cm; continuous rotation; angular sampling, 3°; duration, 28 min) in
patient and control groups. Brain sections were reconstructed with an
iterative algorithm (ordered subset expectation maximization, four iter-
ations and 15 subsets), followed by 3D filtering of sections obtained
(Butterworth, order 5, cutoff 0.31 Ny) and attenuation correction
(Chang method, factor 0.12).
Imaging data processing. The reconstructed images were analyzed for
regionally specific FP-CIT binding using Statistical Parametric Mapping
(SPM2; Wellcome Department of Imaging Neuroscience, London, UK)
in conjunction with MATLAB version R2007a (Mathworks).
First, we created a group-specific 123I-FP-CIT SPECT template with
SPM2 by spatially normalizing the FP-CIT images of 15 healthy subjects
onto a 18F-FP-CIT PET MNI-based template as previously described
(Ma et al., 2002; Isaias et al., 2010), averaging the normalized images and
their symmetric (mirror) image and filtering using a 3D Gaussian kernel
with 8mm full width at halfmaximum (FWHM) (Kas et al., 2007). Then,
the FP-CIT images of all subjects were spatially normalized onto this
FP-CIT template and smoothed with a FWHM 10 mm Gaussian kernel
to increase the signal-to-noise ratio and to account for subtle variations
in anatomic structures. For each individual FP-CIT SPECT image, a
parametric binding ratio image was calculated using the ImCalc toolbox
in SPM. Binding values for each FP-CIT image were computed in a
voxel-by-voxel manner [(voxel" occipital)/occipital]. The reference re-
gion in the occipital cortex was defined using the volume-of-interest of
superior, middle, and inferior occipital gyri and calcarine gyri of the
automated anatomical labeling (Tzourio-Mazoyer et al., 2002), using the
Wake Forest University PickAtlas 2.4 software.
Voxelwise statistical analysis. A general linear model was used to per-
form the appropriate voxelwise statistics using SPM2 inwhole brain of all
subjects. The analysis was applied to SPECT images by means of single-
subject: conditions and covariates design. The PD patients and healthy
controls weremodeled as conditions and the covariates were the scores of
acquisition and transfer for both adaptation and curvature. In addition,
we performed a covariance analysis between the transfer scores and FP-
CIT SPECT images. In every analysis, we used no global normalization,
no grand mean scaling, and threshold masking absolute of#1. For t test
in PD versus healthy controls (HC), p $ 0.001 with false discovery rate
correction was considered significant and for covariance analysis, p $
0.01 uncorrected was significant, both at clusters of at least 50 voxels. All
coordinates are reported in MNI space.
General statistical analysis.Normality of data distributionwas tested by
the Shapiro-Wilks test. Gender distribution among groups was tested
with ! square. Demographic data were compared by means ofWilcoxon
two-group test. A multivariate pairwise correlation analysis was used to
investigate statistical dependence among SPECT binding values demo-
graphic, clinical, and behavioral data. Statistical analyses were performed
with the JMP statistical package, version 8.0.2 (SAS Institute).
Results
In the first 10 blocks, patients and controls gradually decreased
their directional error at peak velocity and adapted to the imposed
rotation at a similar rate (Block: F(9,171) % 165.52, p $ 0.00001;
Group: F(1,19)% 1.70, p% 0.20; Block!Group: F(9,171)% 0.25, p%
0.99; Fig. 1a). The degree of total adaptation achieved was
comparable in patients (44.1% & 2.7%) and controls (45.7% &
2.9%; F(1,19)% 0.14, p% 0.71).
Both groups showed a similar and significant reduction in
curvature across blocks (Block: F(9,171) % 15.77, p $ 0.00001;
Group: F(1,19) % 0.59, p % 0.45; Block ! Group: F(9,171) % 0.31,
p % 0.97; Fig. 1b), further indicating that adaptation indeed re-
sulted fromupdating the internalmodel with reduced reliance on
online corrections.
The transfer of adaptation to the performance with the left
hand was lower in patients compared with controls (PD: 71.4&
4.6 vs HC: 85.5& 2.4, mean& SE; F(1,19)% 5.82, p% 0.03), while
the transfer of curvature was similar in the two groups (PD: 2&
0.6 vs HC: 1.9& 0.6, mean& SE; F(1,19)% 0.07, p% 0.80).
In the subgroup of subjects tested 3 weeks later, we found that
aftereffects were significantly larger in controls ("7.49 & 3.40°)
than in patients with PD, where such effects were virtually absent
("0.29& 3.78°; F(1,13)% 15.01; p% 0.002).
A significant, althoughweak, correlation ("% 0.53, p$ 0.025)
was found between the 3 week aftereffects and right-to-left hand
transfer.
No correlation was found between behavioral and clinical or
demographic data. In particular, we found no correlations be-
tween transfer of adaptation andUPDRS-III ("% 0.22; p% 0.51),
UPDRS-AK ("%"0.18; p% 0.58), andUPDRS-item 22 (rigidity
score left: "%"0.45, p% 0.15; rigidity score right: "% 0.15, p%
0.64), suggesting that the learning and transfer indices are not
predicted by clinical signs of PD. In addition, transfer of adapta-
tion did not correlate with age ("%"0.33, p% 0.31) or disease
duration ("%"0.06, p% 0.84).
Figure 2. a, b, Whole-brain voxelwise statistical analysis (SPM) showing a positive correla-
tion between transfer of adaptation and DAT density in the right caudate (x, y, z: 16, 8, 14) and
right putamen (x, y, z: 32, 4,"2). c, d, A volume of interest analysis confirming a positive
correlation for the right caudate nucleus ("% 0.74, p$ 0.01) and right putamen ("% 0.71,
p% 0.01).
Table 2. DAT binding values
CN right CN left PT right PT left
PD 1.21& 0.16 (0.99–1.51)* 1.2& 0.18 (0.99–1.46)* 1.74& 0.26 (1.2–2.1)* 1.92& 0.32 (1.47–2.42)*
HC 1.77& 0.29 (1.15–2.1) 1.59& 0.33 (1.19–2.04) 2.54& 0.32 (1.85–3.04) 2.79& 0.35 (2.06–3.47)
Subjectswith PD showed a significant reduction of DATbinding values in both the caudate nucleus (CN) andputamen (PT) bilaterallywhen compared to a group of 15HC. Data are reported asmean& SD and range (in brackets). *p$ 0.001.
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Binding values are listed in Tables 1 and 2. On average, PD
subjects showed a reducedDAT binding value of 32% in the right
caudate, 25% in the left caudate, and 32% in both right and left
putamen. AverageDATbinding losswas not statistically different
between left and right striatum.
Whole-brain SPM analysis revealed a selective positive corre-
lation between the transfer of adaptation, but not of curvature,
and DAT binding values of the right caudate and putamen only
(Fig. 2, a and b, respectively). These results were confirmed by a
volume of interest analysis (transfer of adaptation and right cau-
date: ! ! 0.74, p " 0.01; transfer of adaptation and right puta-
men: !! 0.71, p! 0.01; Fig. 2, c and d, respectively).
No correlation was found between the adaptation rate of the
right hand and DAT binding of any brain areas.
Discussion
The main result of this study is that the transfer of visuomotor
learning correlated with DAT binding of the right striatum, sug-
gesting, for the first time, that the levels of striatal dopamine
influence the degree of interlimb transfer of a visuomotor skill.
In agreement with previous studies with similar paradigms
(Marinelli et al., 2009; Be´dard and Sanes, 2011; Venkatakrishnan
et al., 2011) or prism adaptation (Weiner et al., 1983; Stern et al.,
1988), patients with PD adapted their movements to an applied
visual distortion similarly to healthy subjects. This visuomotor
learning occurred by decreasing both initial directional error and
hand path curvature. The decrement of both measures suggests
that adaptation was achieved by the progressive modification of
the motor plan and not by the constant use of online corrections
of the trajectory.
When we tested the left hand, PD patients showed a reduced
transfer of visuomotor learning compared with controls. The de-
gree of transfer positively correlatedwith the values ofDATbind-
ing of the right striatum, but was not predicted by the UPDRS
scores. Therefore, the observed deficit in transfer cannot be as-
cribed to a disease-related motor impairment, but depends on
the dopaminergic innervation itself.
The specificmechanisms underlying interlimb transfer of visuo-
motor adaptation are still largely unknown. Adapting to a visuomo-
tor rotation is likely to involve both effector-independent and
effector-specific processes. The former consist of the progressive
creation of new mapping between the direction of the hand tra-
jectory and of the target, expressed in visual coordinates and
therefore independent of the characteristics of the actual effector
(i.e., the limb). The latter consist of the selection and implemen-
tation of the appropriate dynamic motor commands that trans-
late the new motor plan into the actual muscle-activation
patterns, which are specific for the effector involved. Training
with one hand, therefore, likely promotes the formation of both a
visuospatial memory, which can be shared by different effectors,
and an effector-specific visuomotor memory. Therefore, we can
assume that interlimb transfer is possible as the untrained hand
can access the newly formed visual mapping. The fact that trans-
fer is not complete, at least at the beginning of a task, implies that
the formation of an effector-specific memory is also essential to
complete the adaptation process. The reduced amount of transfer
that we found in patients with PD could be due to impairments in
both the formation and retrieval of the new visuospatial map, as
well as in the efficient conversion of such a map to the untrained
arm. Of note, the clinical signs in our patients were bilateral and
of comparable severity, as also shown by similar DAT binding
loss in both right and left striatum. Therefore, the reduced inter-
limb transfer should not be ascribed to a differential impairment
of the two limbs. In this and previous studies (Marinelli et al.,
2009), we also found that PD patients display an impairment of
the long-term retention of this visuomotor skill that, in the pres-
ent patient population, is highly correlated with the degree of
transfer. Thus, it is possible that the reduced transfer in PD is part
of a general deficit in skill formation, retention, and retrieval.
Despite adaptation rates within normal limits, it is possible that
the formation of a stable memory trace is not effective in patients
with PD, thus impairing short- and long-term memory pro-
cesses. Accordingly, animal studies suggested a central role of
striatal dopaminergic innervation in skill formation (Graybiel,
1998) and strengthening of synaptic plasticity (Calabresi et al.,
2000; Lovinger et al., 2003).
The correlation found between the magnitude of the transfer
and the dopamine levels was confined to the right striatum. Such
lateralization could be explained by the direction of the transfer,
from the right to the left hand. However, other theories should
consider the right-hemisphere dominancy for this task (Ghilardi
et al., 2000; Huber et al., 2004; Seidler et al., 2008) and for visu-
ospatial abilities in general (Heilman et al., 1986). Future studies
on the transfer in the opposite direction (left hand toward right
hand) could settle the question of hemispheric dominance in this
task. So far, studies with our task (Ghilardi et al., 2000; Huber et
al., 2004) or similar paradigms (Seidler at al. 2008) showed that
activity in the right-hemisphere, and in particular in the right
parietal cortex, is essential for the formation and the retention of
a new visuospatial mapping. Retrieval of the learned visuospatial
skill could thus involve both cortical and striatal structures on the
right. It is important to note that this study aimed at specifically
examining the role of dopamine in interlimb transfer and not the
related anatomical network. Future studies will investigate whether
such a transfer relies on transcallosal projections from the cortex
(e.g., right parietal cortex) to the ipsilateral and contralateral stria-
tum, or a direct interstriatal transfer through the anterior commis-
sure (Steiner et al., 1985).
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